[go: up one dir, main page]

WO2025118034A1 - Composés actifs au niveau du récepteur sérotonergique 5-ht2a - Google Patents

Composés actifs au niveau du récepteur sérotonergique 5-ht2a Download PDF

Info

Publication number
WO2025118034A1
WO2025118034A1 PCT/AU2024/051322 AU2024051322W WO2025118034A1 WO 2025118034 A1 WO2025118034 A1 WO 2025118034A1 AU 2024051322 W AU2024051322 W AU 2024051322W WO 2025118034 A1 WO2025118034 A1 WO 2025118034A1
Authority
WO
WIPO (PCT)
Prior art keywords
cycloalkyl
heterocycloalkyl
alkyl
haloalkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/AU2024/051322
Other languages
English (en)
Inventor
William JORGENSON
Jinlong Tan
Lachlan WHISH
Samuel BANISTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psylo Pty Ltd
Original Assignee
Psylo Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2023903954A external-priority patent/AU2023903954A0/en
Application filed by Psylo Pty Ltd filed Critical Psylo Pty Ltd
Publication of WO2025118034A1 publication Critical patent/WO2025118034A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/52—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/10—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present disclosure relates generally to compounds active at the serotonergic 5-HT2A receptor that may be useful in the treatment of mental illness or central nervous system disorders.
  • the disclosure also relates to methods of synthesis of the compounds, compositions comprising the compounds and to methods for their use
  • serotonergic drugs such as antidepressants, serotonin reuptake inhibitors, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and others are commercially available to treat mental illnesses.
  • these therapeutics provide limited benefit when compared to a placebo. Additionally, these therapeutics can result in a wide range of side effects including loss of libido, insomnia, fatigue, weight gain, and others.
  • these drugs continue to be used to treat neuropsychiatric conditions as well as a broad range of auxiliary medical indications. There have been limited advances in new treatment options since many of these drugs were released, and the pharmaceutical industry has come under increased financial pressure to de-emphasise neuroscience programmes entirely.
  • Psilocybin is rapidly metabolized to the bioactive compound psilocin, which produces a state of altered consciousness including changes in perception, visual hallucinations, and distorted sense of space, time, and self. Many patients report spiritual or “mystical” experiences which have profound and lasting impact on the patients’ mood and behaviour. Psilocybin has shown promise in more than 50 clinical trials for neuropsychiatric indications, including numerous anxiety disorders, obsessive- compulsive disorder, anorexia nervosa, alcohol dependence, and tobacco addiction.
  • Psilocybin and other psychedelic compounds such as N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) have both immediate and persistent effects on mental state, with the latter extending far beyond the duration of action, possibly as a result of their ability to incite increased neuroplasticity, promote neural outgrowth, and increase spine density of the synaptic neurons in the brain.
  • DMT N,N-dimethyltryptamine
  • 5-MeO-DMT 5-methoxy-N,N-dimethyltryptamine
  • 5-HT2A the primary target
  • 5-HT2B receptors a cardiac liability antitarget
  • 5-HT1A an anxiolytic target
  • 5-HT2C receptors a disease-relevant target for obesity and some genetic epilepsies, for example
  • the present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph and/or prodrug thereof, wherein L is selected from C 1 -4 alkylene, C 2 -4 alkenylene and C 2 -4 alkynylene; R 1 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 3-8 cycloalkyl, C4-14 alkylenecycloalkyl, C 3 -C 8 heterocycloalkyl, C 4 -C 14 alkyleneheterocycloalkyl, C 6-12 aryl, C 7-18 alkylenearyl, C 5- 10 heteroaryl, and C 6-16 alkyleneheteroaryl, said C 1-6 alkyl, or a pharmaceutical
  • the present disclosure provides a medicament comprising a compound according to any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.
  • a pharmaceutical composition comprising a compound according to any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, and a pharmaceutically acceptable excipient.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, an additional therapeutic agent, and a pharmaceutically acceptable excipient.
  • the present disclosure provides a method of treating a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I) as defined in any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.
  • the present disclosure provides a method of treating a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I) as defined in any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor.
  • the present disclosure provides a method of treating a mental illness, the method comprising administering to a subject in need thereof a compound of formula (I) as defined in any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.
  • the mental illness is selected from anxiety disorders; depression; mood disorders; psychotic disorders; impulse control and addiction disorders; drug addiction; obsessive-compulsive disorder (OCD); post-traumatic stress disorder (PTSD); stress response syndromes; dissociative disorders; depersonalization disorder; factitious disorders; sexual and gender disorders; somatic symptom disorders; hallucinations; delusions; psychosis; and combinations thereof.
  • the present disclosure provides a method for treating a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition, the method comprising administering to a subject in need thereof a compound of formula (I) as defined in any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.
  • CNS central nervous system
  • the CNS disease, disorder or condition and/or neurological disease, disorder or condition is selected from neurological diseases including neurodevelopmental diseases and neurodegenerative diseases such as Alzheimer’s disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson’s disease and Parkinsonian related disorders such as Parkinson dementia, corticobasal degeneration, and supranuclear palsy; epilepsy; CNS trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington’s disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder and attention deficit disorders; restless leg syndrome; Tourette's syndrome; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system including eating disorders such as anorexia nervos
  • the present disclosure provides a method for increasing neuronal plasticity and/or increasing dendritic spine density, the method comprising contacting a neuronal cell with a compound of formula (I) as defined in any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, in an amount sufficient to increase neuronal plasticity and/or increase dendritic spine density of the neuronal cell.
  • the present disclosure provides methods of treating weight, comprising administering an effective amount of a compound of the invention to a subject in need thereof.
  • Treatment of weight may include treating weight gain; weight loss; metabolic disorder; weight gain associated with pharmaceutical intervention; weight gain associated with a mental illness (including those described herein); eating disorders such as anorexia, bulimia, cachexia, etc.; eating behaviour; obesity; diabetes; insulin resistance; pre-diabetes; glucose intolerance; hyperlipidemia; and cardiovascular disease.
  • the present disclosure provides a method for activating a serotonin receptor in a cell, either in a biological sample or in a patient, comprising administering a compound of formula (I) as defined in any one of the herein disclosed embodiments to the cell. Any embodiment herein shall be taken to apply mutatis mutandis to any other embodiment unless specifically stated otherwise.
  • treatment or “treating” of a subject includes delaying, slowing, stabilizing, curing, healing, alleviating, relieving, altering, remedying, less worsening, ameliorating, improving, or affecting the disease or condition, the sign or symptom of the disease or condition, or the risk of (or susceptibility to) the disease or condition.
  • treating refers to any indication of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; lessening of the rate of worsening; lessening severity of the disease; stabilization, diminishing of signs or symptoms or making the injury, pathology or condition more tolerable to the individual; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating.
  • the methods of the present invention can be to prevent or reduce the severity, or inhibit or minimise progression, of a sign or symptom of a disease or condition as described herein. As such, the methods of the present invention have utility as treatments as well as prophylaxes.
  • preventing or “prevention” is intended to refer to at least the reduction of likelihood of the risk of (or susceptibility to) acquiring a disease or disorder (i.e., causing at least one of the clinical signs or symptoms of the disease not to develop in an individual that may be exposed to or predisposed to the disease but does not yet experience or display signs or symptoms of the disease).
  • Biological and physiological parameters for identifying such patients are provided herein and are also well known by physicians.
  • the term “subject” or “patient” can be used interchangeably with each other.
  • the term “individual” or “patient” refers to an animal that is treatable by the compound and/or method, respectively, including but not limited to, for example, dogs, cats, horses, sheep, pigs, cows, and the like, as well as human, non-human primates. Unless otherwise specified, the “subject” or “patient” may include both male and female genders. Further, it also includes a subject or patient, preferably a human, suitable for receiving treatment with a pharmaceutical composition and/or method of the present invention.
  • selective means a greater activity against a first target (e.g., a 5-HT receptor subtype) relative to a second target (e.g., a second 5-HT receptor subtype).
  • a compound has a selectivity of at least 1.25-fold, at least 1.5 fold, at least 2- fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 10- fold or at least 100-fold greater towards a first target relative to a second target.
  • a compound described herein is selective towards the 5-HT2A receptor relative to one or more other 5-HT receptor subtypes such as 5-HT2B and/or 5-HT2C, preferably 5-HT2B.
  • a compound described herein is selective towards the 5-HT2c receptor relative to one or more other 5-HT receptor subtypes such as 5-HT2A and/or 5-HT2B, preferably 5-HT2B.
  • alkyl refers to a straight or branched chain hydrocarbon radical having from one to twelve carbon atoms, or any range between, i.e. it contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms.
  • the alkyl group is optionally substituted with substituents.
  • alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, and the like.
  • C 1 -C 2 alkyl refers to an alkyl group, as defined herein, containing at least 1, and at most 2, 3 or 6 carbon atoms respectively, or any range in between (eg alkyl groups containing 2-5 carbon atoms are also within the range of C 1 -C 6 ).
  • alkylene refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated, and linking at least two other groups, i.e., a divalent hydrocarbon radical.
  • the two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene group.
  • a straight chain alkylene can be the bivalent radical of –(CH 2 )n–, where n is 1, 2, 3, 4, 5 or 6.
  • Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene.
  • alkenyl whether it is used alone or as part of another group, means a straight or branched chain, saturated alkylene group, that is, a saturated carbon chain that contains substituents on two of its ends.
  • the number of carbon atoms that are possible in the referenced alkylene group are indicated by the prefix “Cn1-n2”.
  • C 2-6 alkylene means an alkylene group having 2, 3, 4, 5 or 6 carbon atoms.
  • alkenyl groups include, but are not limited to, vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2- pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3- hexenyl, 1,3-hexadienyl, 1 ,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5- hexatrienyl.
  • alkynyl as used herein, whether it is used alone or as part of another group, means straight or branched chain, unsaturated alkynyl groups containing at least one triple bond.
  • the number of carbon atoms that are possible in the referenced alkyl group are indicated by the prefix “Cn1-n2”.
  • C 2-6 alkynyl means an alkynyl group having 2, 3, 4, 5 or 6 carbon atoms.
  • alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3- hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5- hexatriynyl.
  • cycloalkyl is intended to include mono-, bi- or tricyclic alkyl groups.
  • the number of carbon atoms that are possible in the referenced cycloalkyl group are indicated by the prefix “Cn1-n2”.
  • C 3-8 cycloalkyl means an cycloalkyl group having 3, 4, 5, 6, 7 or 8 carbon atoms.
  • cycloalkyl groups have from 3 to 12, from 3 to 10, from 3 to 8, from 3 to 6, from 3 to 5 carbon atoms in the ring(s).
  • cycloalkyl groups have 5 or 6 ring carbon atoms.
  • Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • the cycloalkyl group has from 3 to 8, from 3 to 7, from 3 to 6, from 4 to 6, from 3 to 5, or from 4 to 5 ring carbon atoms.
  • Bi- and tricyclic ring systems include bridged, spiro, and fused cycloalkyl ring systems.
  • bi- and tricyclic ring cycloalkyl systems include, but are not limited to, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, adamantyl, and decalinyl.
  • alkylenecycloalkyl refers to a radical having an alkyl component and a cycloalkyl component, where the alkyl component links the cycloalkyl component to the point of attachment ⁇
  • the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the cycloalkyl component and to the point of attachment. In some instances, the alkyl component can be absent.
  • the alkyl component can include any number of carbons, such as C 1-6 , C 1 -2, C 1 -3, C 1 -4, C 1 -5, C 2 -3, C 2 -4, C 2 -5, C 2-6 , C 3 -4, C 3 -5, C 3-6 , C4-5, C4-6 and C5-6.
  • the cycloalkyl component is as defined herein.
  • the numerical range from x to y in “Cx-y alkylenecycloalkyl” relates to the total number of alkyl carbons and cycloalkyl ring atoms.
  • alkylenecycloalkyl groups include, but are not limited to, methylenecyclopropyl, methylenecyclobutyl, methylenecyclopentyl and methylenecyclohexyl.
  • aryl refers to an aromatic ring system having any suitable number of ring atoms and any suitable number of rings. The number of carbon atoms that are possible in the referenced aryl group are indicated by the prefix “Cn1-n2”.
  • C 6-12 aryl means an aryl group having 6, 7, 8, 9, 10, 11 or 12 carbon atoms.
  • Aryl groups can include any suitable number of ring atoms, such as, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms, as well as from 6 to 10, 6 to 12, or 6 to 14 ring members.
  • Aryl groups can be monocyclic, fused to form bicyclic or tricyclic groups, or linked by a bond to form a biaryl group.
  • Representative aryl groups include phenyl, naphthyl and biphenyl.
  • Other aryl groups include benzyl, having a methylene linking group.
  • Some aryl groups have from 6 to 12 ring members, such as phenyl, naphthyl or biphenyl.
  • Other aryl groups have from 6 to 10 ring members, such as phenyl or naphthyl.
  • alkylenearyl refers to a radical having an alkyl component and an aryl component, where the alkyl component links the aryl component to the point of attachment.
  • the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the aryl component and to the point of attachment.
  • the alkyl component can include any number of carbons, such as C 1-6 , C 1 - 2, C 1 -3, C 1 -4, C 1 -5, C 1-6 , C 2 -3, C 2 -4, C 2 -5, C 2-6 , C 3 -4, C 3 -5, C 3-6 , C4-5, C4-6 and C5-6.
  • the alkyl component can be absent.
  • the aryl component is as defined above.
  • the numerical range from x to y in “Cx-y alkylenearyl” relates to the total number of alkyl carbons and aryl ring atoms. Examples of alkylenearyl groups include, but are not limited to, benzyl and ethylenephenyl.
  • alkoxy refers to an alkyl group as defined herein covalently bound via an O linkage.
  • the alkoxy group is optionally substituted with substituents.
  • Examples of “alkoxy” as used herein include, but are not limited to methoxy, ethoxy, propoxy, isoproxy, butoxy, iso-butoxy, tert-butoxy and pentoxy.
  • C 1 -C 2 alkoxy refers to an alkoxy group, as defined herein, containing at least 1, and at most 2, 3 or 6 carbon atoms respectively, or any range in between (eg alkoxy groups containing 2-5 carbon atoms are also within the range of C 1 -C 6 ).
  • alkylamine refers to an alkyl group as defined herein having one or more amino groups. The amino groups can be primary, secondary or tertiary. The alkyl amine can be further substituted with a hydroxy group to form an amino-hydroxy group.
  • alkylamines include, but are not limited to, ethyl amine, propyl amine, isopropyl amine, ethylene diamine and ethanolamine.
  • the amino group can link the alkyl amine to the point of attachment with the rest of the compound, be at the omega position of the alkyl group, or link together at least two carbon atoms of the alkyl group.
  • C 1 -C 2 alkylamine refers to an alkylamine group, as defined herein, containing at least 1, and at most 2, 3 or 6 carbon atoms respectively, or any range in between (e.g., alkylamine groups containing 2-5 carbon atoms are also within the range of C 1 -C 6 ).
  • alkylsulfonyl refers to an alkyl group as defined herein having one or more sulfonyl groups.
  • the sulfonyl group can link the alkylsulfonyl to the point of attachment with the rest of the compound, be at the omega position of the alkyl group, or link together at least two carbon atoms of the alkyl group.
  • the terms " C 1 -C 2 alkylsulfonyl", “C 1 -C 3 alkylsulfonyl” and “C 1 -C 6 alkylsulfonyl” refer to an alkylsulfonyl group, as defined herein, containing at least 1, and at most 2, 3 or 6 carbon atoms respectively, or any range in between (e.g., alkylsulfonyl groups containing 2-5 carbon atoms are also within the range of C 1 -C 6 ).
  • heteroatom as used herein means an atom of any element other than carbon or hydrogen.
  • heteroatoms include nitrogen, oxygen, sulfur and phosphorus.
  • Preferred heteroatoms include N, O and S, preferably N and O.
  • heteroromoiety as used herein means a chemical group comprising a heteroatom.
  • heteromoieties include O, S, S(O), SO 2 , N and NH.
  • a substituted moiety may include 1, 2, 3, 4, 5 or 6 substituents, preferably 1, 2, 3 or 4, more preferably 1, 2 or 3, 1 or 2 or only 1 substituent.
  • a "ring substituent” may be a moiety such as a halogen, alkyl group, or other substituent described herein that is covalently bonded to an atom, preferably a carbon or nitrogen atom, that is a ring member.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated substituents, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound, ie, a compound that can be isolated, characterized and tested for biological activity.
  • optionally substituted or “may be substituted” and the like, as used throughout the specification, denotes that the group may or may not be further substituted or fused (so as to form a polycyclic system), with one or more non-hydrogen substituent groups. Suitable chemically viable substituents for a particular functional group will be apparent to those skilled in the art.
  • substituents include but are not limited to C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 hydroxyalkyl, C 3 -C 7 heterocyclyl, C 3 -C 7 cycloalkyl, C 1 - C 6 alkoxy, C 1 -C 6 alkylsulfanyl, C 1 -C 6 alkylsulfenyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfonylamino, arylsulfonoamino, alkylcarboxy, alkylcarboxyamide, oxo, hydroxy, mercapto, amino, acyl, carboxy, carbamoyl, aryl, aryloxy, heteroaryl, aminosulfonyl, aroyl, aroylamino, heteroaroyl, acyloxy
  • the substituents include amino, halo, C 1 -C 6 alkyl, amido, hydroxyl.
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) and the term “halo” refers to the halogen radicals fluoro (-F), chloro (- Cl), bromo (-Br), and iodo (-I).
  • halo is fluoro or chloro.
  • haloalkyl refers to an alkyl group as defined herein in which one or more (up to all) of the available hydrogen atoms have been replacd with a halogen.
  • perfluoro can be used to define a compound or radical where all the hydrogens are replaced with fluorine.
  • perfluoromethyl refers to 1,1,1 -trifluoromethyl.
  • C 1 -C 2 haloalkyl refers to a haloalkyl group, as defined herein, containing at least 1, and at most 2, 3 or 6 carbon atoms respectively, or any range in between (e.g. haloalkyl groups containing 2-5 carbon atoms are also within the range of C 1 -C 6 ).
  • a C 1 haloalkyl group could be, but is not limited to, fluoromethyl, or difluoromethyl, or trifluoromethyl.
  • haloalkenyl refers to an alkenyl group as defined above in which one or more of the available hydrogen atoms have been replaced with a halogen.
  • C 1-6 haloalkenyl (or “C 1 -C 6 haloalkenyl”) refers to a C 1 to C 6 linear or branched alkenyl group as defined above with one or more halogen substituents.
  • haloalkynyl refers to an alkynyl group as defined above in which one or more of the available hydrogen atoms have been replaced with a halogen.
  • C 1-6 haloalkynyl (or “C 1 -C 6 haloalkynyl”) refers to a C 1 to C 6 linear or branched alkynyl group as defined above with one or more halogen substituents.
  • haloalkoxy refers to an alkoxy group as defined herein substituted with at least one halogen.
  • amino or “amine” refers to the group -NH 2 .
  • substituted amino or “secondary amino” refers to an amino group having a hydrogen replaced with, for example a C 1 -C 6 alkyl group (“C 1 -C 6 alkylamino”), an aryl or aralkyl group (“arylamino”, “aralkylamino”) and so on.
  • C 1 -C 3 alkylamino groups are preferred, such as for example, methylamino (NHMe), ethylamino (NHEt) and propylamino (NHPr).
  • disubstituted amino or “tertiary amino” refers to an amino group having the two hydrogens replaced with, for example aC 1 -C 6 alkyl group, which may be the same or different (“dialkylamino”), an aryl and alkyl group (“aryl(alkyl)amino”) and so on.
  • Di(C 1 -C 3 alkyl)amino groups are preferred, such as for example, dimethylamino (NMe2), diethylamino (NEt2), dipropylamino (NPr 2 ) and variations thereof (eg N(Me)(Et) and so on).
  • nitro refers to the group – NO 2 .
  • cyano and “nitrile” refer to the group –CN.
  • amido or “amide” refers to the group -C(O)NH 2 .
  • substituted amido or “substituted amide” refers to an amido group having a hydrogen replaced with, for example a C 1 -C 6 alkyl group (“C 1 -C 6 alkylamido” or “C 1 -C 6 alkylamide”), an aryl (“arylamido”), aralkyl group (“aralkylamido”) and so on.
  • C 1 - C 3 alkylamide groups are preferred, such as for example, methylamide (-C(O)NHMe), ethylamide (-C(O)NHEt) and propylamide (-C(O)NHPr) and includes reverse amides thereof (eg NHMeC(O)-, -NHEtC(O)- and –NHPrC(O)-).
  • disubstituted amido or “disubstituted amide” refers to an amido group having the two hydrogens replaced with, for example a C 1 -C 6 alkyl group (“di(C 1 -C 6 alkyl)amido” or “di(C 1 -C 6 alkyl)amide”), an aralkyl and alkyl group (“alkyl(aralkyl)amido”) and so on.
  • Di(C 1 -C 3 alkyl)amide groups are preferred, such as for example, dimethylamide (-C(O)NMe2), diethylamide (-C(O)NEt2) and dipropylamide ((-C(O)NPr 2 ) and variations thereof (eg C(O)N(Me)Et and so on) and includes reverse amides thereof.
  • sulfonyl refers to the group -SO 2 H.
  • substituted sulfonyl refers to a sulfonyl group having the hydrogen replaced with, for example a C 1 -C 6 alkyl group (“sulfonylC 1 -C 6 alkyl”), an aryl (“arylsulfonyl”), an aralkyl (“aralkylsulfonyl”) and so on.
  • Sulfonyl C 1 -C 3 alkyl groups are preferred, such as for example, -SO 2 Me, -SO 2 Et and -SO 2 Pr.
  • sulfonylamido or “sulfonamide” refers to the group -SO 2 NH 2 .
  • substituted sulfonamido or “substituted sulphonamide” refers to an sulfonylamido group having a hydrogen replaced with, for example a C 1 -C 6 alkyl group (“sulfonylamidoC 1 -C 6 alkyl”), an aryl (“arylsulfonamide”), aralkyl (“aralkylsulfonamide”) and so on.
  • SulfonylamidoC 1 -C 3 alkyl groups are preferred, such as for example, SO 2 NHMe, SO 2 NHEt and -SO 2 NHPr and includes reverse sulfonamides thereof (e.g.
  • disubstituted sufonamido or “disubstituted sulphonamide” refers to an sulfonylamido group having the two hydrogens replaced with, for example a C 1 -C 6 alkyl group, which may be the same or different (“sulfonylamidodi(C 1 -C 6 alkyl)”), an aralkyl and alkyl group (“sulfonamido(aralkyl)alkyl”) and so on.
  • Sulfonylamidodi(C 1 -C 3 alkyl) groups are preferred, such as for example, -SO 2 NMe2, -SO 2 NEt2 and -SO 2 NPr 2 and variations thereof (eg SO 2 N(Me)Et and so on) and includes reserve sulfonamides thereof (eg –N(Me)SO 2 Me and so on).
  • the term “sulfate” refers to the group OS(O) 2 OH and includes groups having the hydrogen replaced with, for example a C 1 -C 6 alkyl group (“alkylsulfates”), an aryl (“arylsulfate”), an aralkyl (“aralkylsulfate”) and so on.
  • C 1 -C 3 alkylsulfates are preferred, such as for example, OS(O) 2 OMe, OS(O) 2 OEt and OS(O) 2 OPr.
  • the term “sulfonate” refers to the group SO3H and includes groups having the hydrogen replaced with, for example a C 1 -C 6 alkyl group (“alkylsulfonate”), an aryl (“arylsulfonate”), an aralkyl (“aralkylsulfonate”) and so on.
  • C 1 -C 3 alkylsulfonates are preferred, such as for example, SO3Me, SO3Et and SO3Pr.
  • amino acid refers to a moiety containing an amino group and a carboxyl group linked by at least one carbon.
  • An amino acid may refer a natural or non-natural amino acid, preferably a natural amino acid such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, preferably the amino acid is arginine, lysine or histidine, most preferably lysine.
  • carboxylate or “carboxyl” refers to the group -COO- or -COOH.
  • carbamate refers to the group –OC(O)NH 2 .
  • the carbamate may be substituted, or may be disubstituted, for example with an alkyl group such as but not limited to C 1 -C 6 alkyl.
  • carbonate refers to the group –OC(O)O- or –OC(O)OH.
  • alkylcarbonate refers to a carbonate group having the hydrogen replaced with, for example a C 1 -C 6 alkyl group, an aryl or aralkyl group (“arylcarbonate” or “aralkylcarbonate”) and so on.
  • CO3C 1 -C 3 alkyl groups are preferred, such as for example, methylcarbonate (CO3Me), ethylcarbonate (CO3Et) and propylcarbonate (CO3Pr).
  • esters refers to a carboxyl group having the hydrogen replaced with, for example a C 1 -C 6 alkyl group (“carboxylC 1 -C 6 alkyl” or “alkylester”), an aryl or aralkyl group (“arylester” or “aralkylester”) and so on.
  • CO2C 1 -C 3 alkyl groups are preferred, such as for example, methylester (CO2Me), ethylester (CO2Et) and propylester (CO2Pr) and includes reverse esters thereof (eg –OC(O)Me, -OC(O)Et and –OC(O)Pr).
  • heterocyclyl refers to a moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound which moiety has from 3 to 12 ring atoms (unless otherwise specified), of which 1, 2, 3, 4 or more are ring heteroatoms, for example independently selected from O, S and N, or ring heteromoieties, for example independently selected from O, S, S(O), SO 2 , N and NH.
  • a heterocyclyl group contains the prefix Cn1-n2 or “n1 to n2” this prefix indicates the number of carbon atoms in the corresponding carbocyclic group, in which one or more, suitably 1, 2, 3, 4 or more, of the ring atoms is replaced with a heteroatom or heteromoiety.
  • the prefixs 3-, 4-, 5-, 6-, 7-, 8-, 9- and 10- membered denote the number of ring atoms, or range of ring atoms, whether carbon atoms or heteroatoms.
  • C 3 -10 heterocyclyl or “3-10 membered heterocylyl”, as used herein, pertains to a heterocyclyl group having 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms.
  • heterocylyl groups include 5-6-membered monocyclic heterocyclyls and 9- 10 membered fused bicyclic heterocyclyls.
  • Examples of monocyclic heterocyclyl groups include, but are not limited to, those containing one nitrogen atom such as aziridine (3-membered ring), azetidine (4- membered ring), pyrrolidine (tetrahydropyrrole), pyrroline (eg 3-pyrroline, 2,5- dihydropyrrole), 2Hpyrrole or 3H-pyrrole (isopyrrole, isoazole) or pyrrolidinone (5- membered rings), piperidine, dihydropyridine, tetrahydropyridine (6-membered rings), and azepine (7membered ring); those containing two nitrogen atoms such as imidazoline, pyrazolidine (diazolidine), imidazoline, pyrazoline (dihydropyrazole) (5- membered rings), piperazine (6membered ring); those containing one oxygen atom such as oxirane (3-membered ring), oxetane (4
  • Heterocyclyls also encompass heteroaryl (aromatic heterocyclyls) and heterocycloalkyl (non-aromatic heterocyclyls). Such groups may be substituted or unsubstituted.
  • aromatic heterocyclyl may be used interchangeably with the term “heteroaromatic” or the term “heteroaryl” or “hetaryl”.
  • the heteroatoms in the aromatic heterocyclyl group may be independently selected from N, S and O.
  • the aromatic heterocyclyl groups may comprise 1, 2, 3, 4 or more ring heteroatoms.
  • heteroaryl group contains the prefix Cn1-n2 or “n1 to n2” this prefix indicates the number of carbon atoms in the corresponding aryl group, in which one or more, suitably 1, 2, 3, 4 or more, of the ring atoms is replaced with a heteroatom.
  • fused aromatic heterocyclyl groups only one of the rings may contain a heteroatom and not all rings must be aromatic.
  • “Heteroaryl” is used herein to denote a heterocyclic group having aromatic character and embraces aromatic monocyclic ring systems and polycyclic (eg bicyclic) ring systems containing one or more aromatic rings.
  • aromatic heterocyclyl also encompasses pseudoaromatic heterocyclyls.
  • aromatic heterocyclyl refers to a ring system which is not strictly aromatic, but which is stabilized by means of delocalization of electrons and behaves in a similar manner to aromatic rings.
  • aromatic heterocyclyl therefore covers polycyclic ring systems in which all of the fused rings are aromatic as well as ring systems where one or more rings are non-aromatic, provided that at least one ring is aromatic. In polycyclic systems containing both aromatic and non-aromatic rings fused together, the group may be attached to another moiety by the aromatic ring or by a non-aromatic ring.
  • heteroaryl groups are monocyclic and bicyclic groups containing from five to ten ring members.
  • the heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings or two fused five membered rings.
  • Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulphur and oxygen.
  • the heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom.
  • the heteroaryl ring contains at least one ring nitrogen atom.
  • the nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
  • Aromatic heterocyclyl groups may be 5-membered or 6-membered mono-cyclic aromatic ring systems.
  • 5-membered monocyclic heteroaryl groups include but are not limited to furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl (including 1,2,3 and 1,2,4 oxadiazolyls and furazanyl i.e.1,2,5-oxadiazolyl), thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl (including 1,2,3, 1,2,4 and 1,3,4 triazolyls), oxatriazolyl, tetrazolyl, thiadiazolyl (including 1,2,3 and 1,3,4 thiadiazolyls) and the like.
  • Aromatic heterocyclyl groups may also be bicyclic or polycyclic heteroaromatic ring systems such as fused ring systems (including purine, pteridinyl, napthyridinyl, 1H thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl and the like) or linked ring systems (such as oligothiophene, polypyrrole and the like).
  • fused ring systems including purine, pteridinyl, napthyridinyl, 1H thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl and the like
  • linked ring systems such as oligothiophene, polypyrrole and the like.
  • Fused ring systems may also include aromatic 5-membered or 6-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, napthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like, such as 5- membered aromatic heterocyclyls containing nitrogen fused to phenyl rings, 5- membered aromatic heterocyclyls containing 1 or 2 nitrogens fused to phenyl ring.
  • aromatic 5-membered or 6-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, napthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like, such as 5- membered aromatic heterocyclyls containing nitrogen fused to phenyl rings, 5- membered aromatic heterocyclyls containing 1 or 2 nitrogens fused to phenyl ring.
  • a bicyclic heteroaryl group may be, for example, a group selected from: a) a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; b) a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; c) a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; d) a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; e) a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; f) an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; g) an oxazole ring fused to a 5- or 6-membered
  • bicyclic heteroaryl groups containing a five membered ring fused to another five membered ring include but are not limited to imidazothiazole (e.g. imidazo[2,1-b]thiazole) and imidazoimidazole (e.g. imidazo[1,2-a]imidazole).
  • imidazothiazole e.g. imidazo[2,1-b]thiazole
  • imidazoimidazole e.g. imidazo[1,2-a]imidazole
  • bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzofuran, benzothiophene, benzimidazole, benzoxazole, isobenzoxazole, benzisoxazole, benzothiazole, benzisothiazole, isobenzofuran, indole, isoindole, indolizine, indoline, isoindoline, purine (e.g., adenine, guanine), indazole, pyrazolopyrimidine (e.g.
  • pyrazolo[1 ,5-a]pyrimidine benzodioxole and pyrazolopyridine (e.g. pyrazolo[1,5- a]pyridine) groups.
  • pyrazolopyridine groups e.g. pyrazolo[1,5- a]pyridine
  • a further example of a six membered ring fused to a five membered ring is a pyrrolopyridine group such as a pyrrolo[2,3-b]pyridine group.
  • bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.
  • heteroaryl groups containing an aromatic ring and a non-aromatic ring include tetrahydronaphthalene, tetrahydroisoquinoline, tetrahydroquinoline, dihydrobenzothiophene, dihydrobenzofuran, 2,3-dihydro- benzo[1,4]dioxine, benzo[1,3]dioxole, 4,5,6,7-tetrahydrobenzofuran, indoiine, isoindoline and indane groups.
  • aromatic heterocyclyls fused to carbocyclic aromatic rings may therefore include but are not limited to benzothiophenyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzimidazolyl, indazolyl, benzoxazolyl, benzisoxazolyl, isobenzoxazoyl, benzothiazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, benzotriazinyl, phthalazinyl, carbolinyl and the like.
  • heterocycloalkyl or “non-aromatic heterocyclyl” encompasses optionally substituted saturated and unsaturated rings which contain at least one heteroatom such as N, S and O, or a heteromoiety such as O, S, S(O), SO 2 , N and NH.
  • the ring may contain 1, 2, 3, 4 or more heteroatoms or heteromoieties.
  • a heterocycloalkyl group contains the prefix Cn1-n2 or “n1 to n2” this prefix indicates the number of carbon atoms in the corresponding carbocyclic group, in which one or more, suitably 1, 2, 3, 4 or more, of the ring atoms is replaced with a heteroatom or heteromoiety.
  • the ring may be a monocyclic ring or part of a polycyclic ring system.
  • Polycyclic ring systems include fused rings and spirocycles. Not every ring in a non- aromatic heterocyclic polycyclic ring system must contain a heteroatom, provided at least one ring contains one or more heteroatoms.
  • Non-aromatic heterocyclyls may be 3-8 membered mono-cyclic rings.
  • Examples of 5-membered non-aromatic heterocyclyl rings include 2H-pyrrolyl, 1pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3- pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolinyl, 2-pyrazolinyl, 3- pyrazolinyl, pyrazolidinyl, 2-pyrazolidinyl, 3-pyrazolidinyl, imidazolidinyl, 3-dioxalanyl, thiazolidinyl, isoxazolidinyl, 2-imidazolinyl and the like.
  • 6-membered non-aromatic heterocyclyls include piperidinyl, piperidinonyl, pyranyl, dihyrdopyranyl, tetrahydropyranyl, 2H pyranyl, 4H pyranyl, thianyl, thianyl oxide, thianyl dioxide, piperazinyl, diozanyl, 1,4-dioxinyl, 1,4-dithianyl, 1,3,5triozalanyl, 1,3,5-trithianyl, 1,4-morpholinyl, thiomorpholinyl, 1,4-oxathianyl, triazinyl, 1,4thiazinyl and the like.
  • Non-aromatic heterocyclyls examples include azepanyl, oxepanyl, thiepanyl and the like.
  • Non-aromatic heterocyclyl rings may also be bicyclic heterocyclyl rings such as linked ring systems (for example uridinyl and the like) or fused ring systems.
  • Fused ring systems include non-aromatic 5-membered, 6-membered or 7-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, napthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like.
  • alkyleneheteroaryl refers to a radical having an alkyl component and a heteroaryl component, where the alkyl component links the heteroaryl component to the point of attachment ⁇
  • the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the heteroaryl component and to the point of attachment. In some instances, the alkyl component can be absent.
  • the alkyl component can include any number of carbons, such as C 1-6 , C 1 -2, C 1 -3, C 1 -4, C 1 -5, C 2 -3, C 2 -4, C 2 -5, C 2-6 , C 3 -4, C 3 -5, C 3-6 , C4-5, C4-6 and C5-6.
  • the heteroaryl component is as defined herein.
  • the numerical range from x to y in “Cx-y alkylenecycloalkyl” relates to the total number of alkyl carbons and heteroaryl ring atoms (carbon and heteroatoms together).
  • alkyleneheterocycloalkyl refers to a radical having an alkyl component and a heterocycloalkyl component, where the alkyl component links the heterocycloalkyl component to the point of attachment ⁇
  • the alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the heterocycloalkyl component and to the point of attachment. In some instances, the alkyl component can be absent.
  • the alkyl component can include any number of carbons, such as C 1-6 , C 1 -2, C 1 -3, C 1 -4, C 1 -5, C 2 -3, C 2 -4, C 2 -5, C 2-6 , C 3 -4, C 3 -5, C 3-6 , C4-5, C4-6 and C5-6.
  • the heterocycloalkyl component is as defined herein. The numerical range from x to y in “Cx- y alkyleneheterocycloalkyl” relates to the total number of alkyl carbons and heterocycloalkyl ring atoms (carbon and heteroatoms together).
  • solvate refers to a complex of the compound and either stoichiometric or non-stoichiometric amounts of a solvent. Solvates are often formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol.
  • polymorph refers to the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility.
  • the term “metabolite” refers to a derivative of a compound that is formed when the compound is metabolized.
  • active metabolite refers to a biologically active derivative of a compound that is formed when the compound is metabolized.
  • the term “metabolized,” as used herein, refers to the sum of the processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes) by which a particular substance is changed by an organism. Thus, enzymes may produce specific structural alterations to a compound.
  • Metabolites of the compounds disclosed herein are optionally identified either by administration of compounds to a host and analysis of tissue samples from the host, or by incubation of compounds with hepatic cells in vitro and analysis of the resulting compounds.
  • Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994.
  • the compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms.
  • stereoisomers refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
  • stereoisomer includes but is not limited to diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures.
  • pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • suitable inorganic and organic acids and bases include those derived from suitable inorganic and organic acids and bases.
  • pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • the present disclosure provides compounds of formula (I): or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph and/or prodrug thereof, wherein L is selected from C 1 -4 alkylene, C 2 -4 alkenylene and C 2 -4 alkynylene; R 1 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 3-8 cycloalkyl, C4-14 alkylenecycloalkyl, C 3 -C 8 heterocycloalkyl, C 4 -C 14 alkyleneheterocycloalkyl, C 6-12 aryl, C 7-18 alkylenearyl, C5- 10 heteroaryl, and C 6-16 alkyleneheteroaryl, said C 1-6 alkyl, C 1-6 hal
  • the compound is not selected from one or more of the group consisting of: or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, or polymorph thereof.
  • R 4 when R 4 is OH or OMe; then R 1 and R 2 are not both hydrogen.
  • R 4 when R 4 is fluoro; then R 1 and R 2 are not both hydrogen.
  • R 5 when R 5 is OMe; then R 1 and R 2 are not both hydrogen.
  • R 5 is fluoro; then R 1 and R 2 are not both hydrogen.
  • R 6 when R 6 is OH or OMe; then i) R 1 and R 2 are not both hydrogen, and/or ii) R 1 and R 2 are not both C 2 alkyl. In some embodiments, when R 6 is fluoro; then i) R 1 and R 2 are not both hydrogen, and/or ii) if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 2 alkyl. In some embodiments, when R 6 is chloro; then i) R 1 and R 2 are not both hydrogen, and/or ii) if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 2 alkyl.
  • R 6 when R 6 is bromo; then if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 2 alkyl. In some embodiments, when R 6 is OMe; then i) if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 1 alkyl, iso-propyl, sec-butyl or tert-butyl; and/or ii) R 1 and R 2 are not both hydrogen. In some embodiments, when R 6 is bromo; then i) R 1 and R 2 are not both hydrogen, and/or ii) if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 1 alkyl.
  • R 6 when R 6 is fluoro; then if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 1 alkyl. In some embodiments, when R 6 is chloro; then if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 1 alkyl. In some embodiments, when R 6 is OMe; then if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 2 -4alkyl. In some embodiments, when R 8 is OMe or OH; then R 1 and R 2 are not both hydrogen. In some embodiments, when R 8 is OMe; then R 1 and R 2 are not both C 1 alkyl.
  • R 8 when R 8 is OMe; then R 1 and R 2 are not both C 1-6 alkyl. In some embodiments, when R 8 is OMe; then R 1 and R 2 are not both C 1 -2alkyl. In some embodiments, when R 8 is OMe; then R 1 and R 2 are not both C 1 alkyl. In some embodiments, when R 8 is fluoro; then i) R 1 and R 2 are not both hydrogen, and/or ii) if one of R 1 and R 2 is hydrogen then the other one of R 1 and R 2 is not C 1 alkyl. L In some embodiments, L is C 1 -4 alkylene. In some embodiments, L is methylene.
  • R 4 , R 5 , R 6 and R 8 In some embodiments, only one of R 4 , R 5 , R 6 and R 8 is other than hydrogen. In some embodiments, R 4 is other than hydrogen. In some embodiments, R 4 is other than hydrogen and R 5 -R 10 are hydrogen. In some embodiments, R 5 is other than hydrogen. In some embodiments, R 5 is other than hydrogen and R 4 and R 6 -R 10 are hydrogen. In some embodiments, R 6 is other than hydrogen. In some embodiments, R 6 is other than hydrogen and R 4 -R 5 and R 7 -R 10 are hydrogen. In some embodiments, R 8 is other than hydrogen. In some embodiments, R 8 is other than hydrogen and R 4 -R 7 and R 9 -R 10 are hydrogen.
  • R 4 is selected from halogen, CN, OR 13 , N(R 13 ) 2 , SR 13 , C 1 - 6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2 -C 6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 1 - 6 alkylamine, C 1-6 alkoxy, C 1-6 haloalkoxy, CO2R 13 , C(O)R 13 , C(O)N(R 13 ) 2 , C(O)C(O)N(R 13 ) 2 , OC(O)R 13 , OC(O)OR 13 , OC(O)N(R 13 ) 2 , OS(O)R 13 , OS(O)N(R 13 ) 2 , OSO 2 R 13 , OP(O)(OR 13 ) 2 , OC 1-6 alkyleneP(O)(OR 13 , OC
  • R 5 is selected from halogen, CN, OR 13 , N(R 13 ) 2 , SR 13 , C 1 - 6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2 -C 6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 1 - 6 alkylamine, C 1-6 alkoxy, C 1-6 haloalkoxy, CO2R 13 , C(O)R 13 , C(O)N(R 13 ) 2 , C(O)C(O)N(R 13 ) 2 , OC(O)R 13 , OC(O)OR 13 , OC(O)N(R 13 ) 2 , OS(O)R 13 , OS(O)N(R 13 ) 2 , OSO 2 R 13 , OP(O)(OR 13 ) 2 , OC 1-6 alkyleneP(O)(OR 13 , OC
  • R 5 is selected from halogen (eg F), -OH and optionally substituted C 1-6 alkoxy (eg methoxy), and R 4 , R 6 and R 8 are each H.
  • R 5 is selected from F, -OH and optionally substituted methoxy, and R 5 , R 6 and R 8 are each H.
  • R 6 is selected from halogen, CN, OR 13 , N(R 13 ) 2 , SR 13 , C 1 - 6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2 -C 6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 1 - 6 alkylamine, C 1-6 alkoxy, C 1-6 haloalkoxy, CO2R 13 , C(O)R 13 , C(O)N(R 13 ) 2 , C(O)C(O)N(R 13 ) 2 , OC(O)R 13 , OC(O)OR 13 , OC(O)N(R 13 ) 2 , OS(O)R 13 , OS(O)N(R 13 ) 2 , OSO 2 R 13 , OP(O)(OR 13 ) 2 , OC 1-6 alkyleneP(O)(OR 13 , OC
  • R 6 is selected from halogen (eg F), -OH and optionally substituted C 1-6 alkoxy (eg methoxy), and R 4 , R 5 and R 8 are each H. In some embodiments, R 6 is selected from F, -OH and optionally substituted methoxy, and R 4 , R 5 and R 8 are each H.
  • R 8 is selected from halogen, CN, OR 13 , N(R 13 ) 2 , SR 13 , C 1 - 6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2 -C 6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 1 - 6 alkylamine, C 1-6 alkoxy, C 1-6 haloalkoxy, CO2R 13 , C(O)R 13 , C(O)N(R 13 ) 2 , C(O)C(O)N(R 13 ) 2 , OC(O)R 13 , OC(O)OR 13 , OC(O)N(R 13 ) 2 , OS(O)R 13 , OS(O)N(R 13 ) 2 , OSO 2 R 13 , OP(O)(OR 13 ) 2 , OC 1-6 alkyleneP(O)(OR 13 , OC
  • R 8 is selected from halogen (eg F), -OH and optionally substituted C 1-6 alkoxy (eg methoxy), and R 4 , R 5 and R 6 are each H. In some embodiments, R 8 is selected from F, -OH and optionally substituted methoxy, and R 4 , R 5 and R 6 are each H.
  • R 1 and R 2 are each independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 3-8 cycloalkyl, C4-14 alkylenecycloalkyl, C 3 -C 8 heterocycloalkyl, C 4 -C 14 alkyleneheterocycloalkyl, C 6-12 aryl, C 7-18 alkylenearyl, C 5-10 heteroaryl, and C 6-16 alkyleneheteroaryl.
  • R 1 and R 2 are each independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 3-8 cycloalkyl, C4-14 alkylenecycloalkyl and C 7-18 alkylenearyl.
  • R 1 and R 2 are each independently selected from hydrogen, C 1 -4 alkyl, C 1 -4 haloalkyl, C 3 -4 cycloalkyl, C4-5 alkylenecycloalkyl, and C 7 alkylenearyl.
  • R 1 and R 2 are each independently selected from C 1 -4 alkyl, C 1 -4 haloalkyl, C 3 -4 cycloalkyl, C4-5 alkylenecycloalkyl, and C 7 alkylenearyl.
  • R 1 and R 2 are each independently selected from hydrogen, C 1-4 alkyl and C 1-4 haloalkyl; preferably hydrogen and C 1-4 alkyl.
  • R 1 and R 2 are each independently selected from C 1 -4 alkyl.
  • R 1 and R 2 are each independently selected from hydrogen, C4-5 alkylenecycloalkyl, and C 7 alkylenearyl.
  • R 1 and R 2 are each independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, C 2-6 haloalkynyl, C 3-8 cycloalkyl and C4-14 alkylenecycloalkyl. In some embodiments, both of R 1 and R 2 are the same. In some embodiments, each of R 1 and R 2 are different. In some embodiments, one of R 1 and R 2 is unsubstituted. In some embodiments, both of R 1 and R 2 are unsubstituted. In some embodiments, at least one of the alkyl groups at R 1 and R 2 are linear.
  • At least one of R 1 and R 2 is not C 2 alkyl. In some embodiments, both of R 1 and R 2 are not C 2 alkyl. In some embodiments, at least one of R 1 and R 2 is C 2 alkyl. In some embodiments, at least one of R 1 and R 2 is not C 3 alkyl. In some embodiments, both of R 1 and R 2 are not C 3 alkyl. In some embodiments, at least one of R 1 and R 2 is C 3 alkyl. In some embodiments, at least one of R 1 and R 2 is not hydrogen. In some embodiments, both of R 1 and R 2 are not hydrogen. In some embodiments, both of R 1 and R 2 is hydrogen. In some embodiments, both of R 1 and R 2 are hydrogen. In some embodiments, both of R 1 and R 2 are hydrogen.
  • one of R 1 and R 2 is hydrogen and the other one is C 1-6 alkyl. In some embodiments, one of R 1 and R 2 is hydrogen and the other one is not C 1-6 alkyl. In some embodiments, one of R 1 and R 2 is C 1-6 alkyl and the other one is not hydrogen. In some embodiments, one of R 1 and R 2 is hydrogen and the other one is not C 3 - 8 cycloalkyl. In some embodiments, one of R 1 and R 2 is C 3-8 cycloalkyl and the other one is not hydrogen. In some embodiments, one of R 1 and R 2 is hydrogen and the other one is C4-14 alkylenecycloalkyl.
  • one of R 1 and R 2 is hydrogen and the other one is not C4-14 alkylenecycloalkyl. In some embodiments, one of R 1 and R 2 is C4-14 alkylenecycloalkyl and the other one is not C 1-6 alkyl. In some embodiments, one of R 1 and R 2 is C 1-6 alkyl and the other one is C 3-8 cycloalkyl. In some embodiments, one of R 1 and R 2 is C 1-6 alkyl and the other one is not C 3 - 8 cycloalkyl. In some embodiments, R 1 and R 2 , together with the nitrogen to which they are attached, form any one of the following:
  • R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: In some embodiments, R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: In some embodiments, R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: In some embodiments, R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: . In some embodiments, R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: . In some embodiments, R 1 and R 2 together with the atoms to which they are attached form a C 3-8 heterocycloalkyl including 0, 1 or 2 additional ring heteromoieties selected from O, S, S(O), SO 2 , N and NR 11 .
  • R 1 and R 2 together with the atoms to which they are attached form a C4-5 heterocycloalkyl including 0, 1 or 2 additional ring heteromoieties selected from O, S, S(O), SO 2 , N and NR 11 .
  • the heterocyclyl formed by R 1 and R 2 combined with the atoms to which they are attached to does not include any additional ring heteromoieties.
  • the heterocyclyl formed by R 1 and R 2 combined with the atoms to which they are attached is unsubstituted.
  • R 3 , R 1 & R 2 In some embodiments, R 3 is hydrogen.
  • R 4 to R 10 Each of R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 may be the same or different. Preferably, only one of R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is other than H.
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen, halogen, OR 13 , C 1 -4 alkyl, C 1 -4 haloalkyl, C 2 -4 alkenyl, C 2 -4 haloalkenyl, C 2 -4 alkynyl, C 2 -4 haloalkynyl, C 1 -4 alkylamine, C 1 -4 alkoxy and C 1 -4 haloalkoxy.
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen, halogen, OR 13 , C 1 -2 alkyl, C 1 -2 haloalkyl, C 1 -2 alkoxy and C 1 -2 haloalkoxy. In some embodiments, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen, halogen, OR 13 , and C 1 -2 alkyl; preferably hydrogen, halogen and OR 13 ; more preferably hydrogen, fluoro and OR 13 .
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen and OR 13 . In some embodiments, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen, halogen, OH, C 1 -4 alkyl, C 1 -4 haloalkyl, C 2 -4 alkenyl, C 2 -4 haloalkenyl, C 2 -4 alkynyl, C 2 -4 haloalkynyl, C 1 -4 alkylamine, C 1 -4 alkoxy and C 1 -4 haloalkoxy.
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen, halogen, OH, C 1 -2 alkyl, C 1 -2 haloalkyl, C 1 -2 alkoxy and C 1 -2 haloalkoxy. In some embodiments, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen, halogen, OH, and C 1 -2 alkyl; preferably hydrogen, halogen and OR 13 ; more preferably hydrogen, fluoro and OH.
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen and OH. In some embodiments, only one of R 4 , R 5 , R 6 and R 8 is other than hydrogen. In some embodiments, R 4 is other than hydrogen. In some embodiments, R 5 is other than hydrogen. In some embodiments, R 6 is other than hydrogen. In some embodiments, R 8 is other than hydrogen. In some embodiments, R 4 is hydrogen. In some embodiments, R 5 is hydrogen. In some embodiments, R 6 is hydrogen. In some embodiments, R 7 is hydrogen. In some embodiments, R 8 is hydrogen. In some embodiments, R 9 is hydrogen. In some embodiments, R 10 is hydrogen.
  • R 4 is not OR 13 . In some embodiments, R 4 is not OC 1 - 6alkyl. In some embodiments, R 4 is not OMe. In some embodiments, R 5 is not OR 13 . In some embodiments, R 5 is not OC 1 - 6alkyl. In some embodiments, R 5 is not OMe. In some embodiments, R 6 is not OR 13 . In some embodiments, R 6 is not OC 1 - 6alkyl. In some embodiments, R 6 is not OMe. In some embodiments, R 8 is not OR 13 . In some embodiments, R 8 is not OC 1 - 6alkyl. In some embodiments, R 8 is not OMe.
  • R 7 , R 9 and R 10 are each H. In some embodiments, R 9 and R 10 are each H. In some embodiments, R 7 and R 10 are each H. In some embodiments, R 7 is H. In some embodiments, R 9 is H. In some embodiments, R 10 is H. R 11 to R 13 In some embodiments, each R 11 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl and C 2-6 haloalkynyl. In some embodiments, each R 11 is independently selected from hydrogen and C 1-6 alkyl.
  • each R 12 is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl and C 1-6 haloalkyl. In some embodiments, each R 12 is independently selected from hydrogen and C 1-6 alkyl. In some embodiments, each R 13 is independently selected from hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl and C 1-6 haloalkyl. In some embodiments, each R 13 is independently selected from hydrogen and C 1-6 alkyl, preferably hydrogen and C 1 -3 alkyl, more preferably hydrogen and C 1 alkyl. In some embodiments, each R 13 is hydrogen.
  • R 1 , R 2 , R 3 , R 5 and L are as defined herein.
  • L is methylene and R 3 is H.
  • R 5 is selected from OH, OCH 3 and F.
  • R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: .
  • the compound of formula (I) is provided as a compound of formula (IV): wherein R 1 , R 2 , R 3 , R 6 and L are as defined herein.
  • L is methylene and R 3 is H.
  • R 6 is selected from OH, OCH 3 and F.
  • R 6 is selected from OH and F.
  • R 6 is -OH.
  • R 6 is -OCH 3 .
  • R 6 is halo.
  • R 6 is F.
  • R 1 and R 2 together with the nitrogen to which they are attached form any one of the following:
  • one of R 1 and R 2 is H and the other is as defined herein.
  • R 1 is CH 3 .
  • R 2 is CH 3 .
  • each of R 1 and R 2 is CH 3 .
  • the compound of formula (I) is provided as a compound of formula (V):
  • R 1 , R 2 , R 3 , R 8 and L are as defined herein.
  • L is methylene and R 3 is H.
  • R 8 is selected from OH, OCH 3 and F.
  • R 8 is selected from OH and halo.
  • R 8 is selected from OH and F.
  • R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: .
  • one of R 1 and R 2 is H and the other is as defined herein.
  • R 1 is CH 3 .
  • R 2 is CH 3 .
  • each of R 1 and R 2 is CH 3 .
  • the compound of formula (I) is provided as a compound of formula (VI):
  • R 1 , R 2 , R 3 , R 4 , R 6 , R 8 and L are as defined herein.
  • L is methylene.
  • R 3 is H.
  • two of R 4 , R 6 and R 8 are H, and the other of R 4 , R 6 and R 8 is as defined herein with the proviso that it is not H.
  • R 6 is selected from OH, OCH 3 and F.
  • R 4 and R 8 may each be H.
  • R 6 is selected from OH and halo.
  • R 4 and R 8 may each be H.
  • R 6 is selected from OH and F.
  • R 4 and R 8 may each be H.
  • R 4 is selected from OH, OCH 3 and F.
  • R 6 and R 8 may each be H.
  • R 8 is selected from OH, OCH 3 and F.
  • R 4 and R 6 may each be H.
  • R 1 and R 2 together with the nitrogen to which they are attached form any one of the following: .
  • one of R 1 and R 2 is H and the other is as defined herein.
  • each of R 1 and R 2 is H.
  • the compound of the invention is selected from the compounds of Table 1, or a pharmaceutically acceptable salt, solvate, tautomer, N- oxide, stereoisomer and/or prodrug thereof. Table 1: Compounds of the invention
  • the compound of formula (I) is selected from any one of compounds I-1 to I-12, I-44 to I-50, and I-68-76, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof. In some embodiments, the compound of formula (I) is selected from any one of compounds I-44, I-68, I-69, and I-76, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.
  • inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
  • the invention includes all crystalline forms of a compound of Formula (I) including anhydrous crystalline forms, hydrates, solvates and mixed solvates. If any of these crystalline forms demonstrates polymorphism, all polymorphs are within the scope of this invention.
  • Formula (I) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds.
  • Formula (I) includes compounds having the indicated structures, including the hydrated or solvated forms, as well as the non-hydrated and non-solvated forms.
  • the compounds of Formula (I) or salts, tautomers, N-oxides, polymorphs or prodrugs thereof may be provided in the form of solvates.
  • Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, alcohols such as methanol, ethanol or isopropyl alcohol, DMSO, acetonitrile, dimethyl formamide (DMF), acetic acid, and the like with the solvate forming part of the crystal lattice by either non-covalent binding or by occupying a hole in the crystal lattice. Hydrates are formed when the solvent is water, alcoholates are formed when the solvent is alcohol.
  • Solvates of the compounds of the present invention can be conveniently prepared or formed during the processes described herein. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the invention.
  • Basic nitrogen-containing groups may be quarternised with such agents as C 1 - 6alkyl halide, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others. Nitrogen containing groups may also be oxidised to form an N-oxide.
  • the compound of Formula (I) or salts, tautomers, N-oxides, solvates and/or prodrugs thereof that form crystalline solids may demonstrate polymorphism. All polymorphic forms of the compounds, salts, tautomers, N-oxides, solvates and/or prodrugs are within the scope of the invention.
  • the compound of Formula (I) may demonstrate tautomerism. Tautomers are two interchangeable forms of a molecule that typically exist within an equilibrium. Any tautomers of the compounds of Formula (I) are to be understood as being within the scope of the invention.
  • the compound of Formula (I) may contain one or more stereocentres. All stereoisomers of the compounds of formula (I) are within the scope of the invention.
  • Stereoisomers include enantiomers, diastereomers, geometric isomers (E and Z olephinic forms and cis and trans substitution patterns) and atropisomers.
  • the compound is a stereoisomerically enriched form of the compound of formula (I) at any stereocentre.
  • the compound may be enriched in one stereoisomer over another by at least about 60, 70, 80, 90, 95, 98 or 99%.
  • the compound of Formula (I) or its salts, tautomers, solvates, N-oxides, and/or stereoisomers may be isotopically enriched with one or more of the isotopes of the atoms present in the compound.
  • the compound may be enriched with one or more of the following minor isotopes: 2 H, 3 H, 13 C, 14 C, 15 N and/or 17 O, preferably 2 H.
  • An isotope may be considered enriched when its abundance is greater than its natural abundance.
  • a "prodrug” is a compound that may not fully satisfy the structural requirements of the compounds provided herein, but is modified in vivo, following administration to a subject or patient, to produce a compound of formula (I) provided herein.
  • a prodrug may be an acylated derivative of a compound as provided herein.
  • Prodrugs include compounds wherein hydroxy, carboxy, amine or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy, carboxy, amino, or sulfhydryl group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate, phosphate and benzoate derivatives of alcohol and amine functional groups within the compounds provided herein.
  • Prodrugs of the compounds provided herein may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved in vivo to generate the parent compounds.
  • Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (eg, two, three or four) amino acid residues which are covalently joined to free amino, and amido groups of compounds of Formula (I).
  • the amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvlin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone.
  • Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of Formula (I) through the carbonyl carbon prodrug sidechain.
  • Compositions, formulations and modes of administration The compounds of formula (I) can be administered alone or in the form of a pharmaceutical composition.
  • the compounds of formula (I) are usually administered in the form of pharmaceutical compositions, that is, in admixture with at least one pharmaceutically acceptable excipient.
  • the proportion and nature of any pharmaceutically acceptable excipient(s) are determined by the properties of the selected compound of the invention, the chosen route of administration, and standard pharmaceutical practice.
  • compositions of the disclosure typically include a therapeutically effective amount of one or more active ingredients in admixture with one or more pharmaceutically and physiologically acceptable formulation materials.
  • suitable formulation materials include, but are not limited to, antioxidants, preservatives, coloring, flavoring and diluting agents, emulsifying agents, suspending agents, solvents, fillers, bulking agents, buffers, delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants.
  • Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this disclosure.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatine; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil, sesame oil; olive oil; corn oil and soybean oil; glycols; such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminium hydroxide; alginic acid; pyrogenfree water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as
  • Various dosage units are each preferably provided as a discrete dosage tablet, capsules, lozenge, dragee, gum, or other type of solid formulation.
  • Capsules may encapsulate a powder, liquid, or gel.
  • the solid formulation may be swallowed, or may be of a suckable or chewable type (either frangible or gum-like).
  • the present invention contemplates dosage unit retaining devices other than blister packs; for example, packages such as bottles, tubes, canisters, packets.
  • the dosage units may further include conventional excipients well-known in pharmaceutical formulation practice, such as binding agents, gellants, fillers, tableting lubricants, disintegrants, surfactants, and colorants; and for suckable or chewable formulations.
  • a compound of formula (I) may be administered in any form and route which makes the compound bioavailable.
  • Compositions described herein may be administered systemically or directly to the site of condition or disease.
  • Compositions described herein may be formulated from compounds according to Formula (I) for any appropriate route of administration including, for example, oral, rectal, nasal, vaginal, topical (including transdermal, buccal, ocular and sublingual), parenteral (including subcutaneous, intraperitoneal, intradermal, intravascular (for example, intravenous), intramuscular, spinal, intracranial, intrathecal, intraocular, periocular, intraorbital, intrasynovial and intraperitoneal injection, intracisternal injection as well as any other similar injection or infusion techniques), inhalation, insufflation, infusion or implantation techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions).
  • compositions described herein may be administered orally, nasally, intravenously, intramuscularly, topically, subcutaneously, rectally, vaginally or by urethral application.
  • Compositions intended for oral use may further comprise one or more components such as sweetening agents, flavouring agents, colouring agents and/or preserving agents in order to provide appealing and palatable preparations.
  • Tablets contain the active ingredient in admixture with physiologically acceptable excipients that are suitable for the manufacture of tablets.
  • excipients include, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate, granulating and disintegrating agents such as corn starch or alginic acid, binding agents such as starch, gelatine or acacia, and lubricating agents such as magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatine capsules wherein the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium such as peanut oil, liquid paraffin or olive oil.
  • Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and/or flavouring agents may be added to provide palatable oral preparations.
  • Such suspensions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, such as sweetening, flavouring and colouring agents, may also be present.
  • Pharmaceutical compositions may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil such as olive oil or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof.
  • Suitable emulsifying agents include naturally- occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides such as sorbitan monoleate, and condensation products of partial esters derived from fatty acids and hexitol with ethylene oxide such as polyoxyethylene sorbitan monoleate.
  • An emulsion may also comprise one or more sweetening and/or flavouring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, propylene glycol, sorbitol or sucrose.
  • Such Formulations may also comprise one or more demulcents, preservatives, flavouring agents and/or colouring agents.
  • a composition may further include one or more components adapted to improve the stability or effectiveness of the applied formulation, such as stabilizing agents, suspending agents, emulsifying agents, viscosity adjusters, gelling agents, preservatives, antioxidants, skin penetration enhancers, moisturizers and sustained release materials. Examples of such components are described in Martindale – The Extra Pharmacopoeia (Pharmaceutical Press, London 1993) and Martin (ed.), Remington's Pharmaceutical Sciences.
  • Formulations may comprise microcapsules, such as hydroxymethylcellulose or gelatine-microcapsules, liposomes, albumin microspheres, microemulsions, nanoparticles or nanocapsules.
  • Preservatives include, but are not limited to, antimicrobials such as methylparaben, propylparaben, sorbic acid, benzoic acid, and formaldehyde, as well as physical stabilizers and antioxidants such as vitamin E, sodium ascorbate/ascorbic acid and propyl gallate.
  • Suitable moisturizers include, but are not limited to, lactic acid and other hydroxy acids and their salts, glycerine, propylene glycol, and butylene glycol.
  • Suitable emollients include lanolin alcohol, lanolin, lanolin derivatives, cholesterol, petrolatum, isostearyl neopentanoate and mineral oils.
  • Suitable fragrances and colours include, but are not limited to, FD&C Red No.40 and FD&C Yellow No.5.
  • Suitable additional ingredients that may be included in a topical Formulation include, but are not limited to, abrasives, absorbents, anticaking agents, antifoaming agents, antistatic agents, astringents (such as witch hazel), alcohol and herbal extracts such as chamomile extract, binders/excipients, buffering agents, chelating agents, film forming agents, conditioning agents, propellants, opacifying agents, pH adjusters and protectants.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzy
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P.
  • injectables can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • a pharmaceutical composition may be formulated as inhaled formulations, including sprays, mists, or aerosols.
  • the composition or combination provided herein may be delivered via any inhalation methods known to a person skilled in the art.
  • inhalation methods and devices include, but are not limited to, metered dose inhalers with propellants such as CFC or HFA or propellants that are physiologically and environmentally acceptable.
  • propellants such as CFC or HFA
  • propellants such as CFC or HFA
  • Other suitable devices are breath operated inhalers, multidose dry powder inhalers and aerosol nebulizers.
  • Aerosol formulations for use in the subject method typically include propellants, surfactants and co-solvents and may be filled into conventional aerosol containers that are closed by a suitable metering valve.
  • Inhalant compositions may comprise liquid or powdered compositions containing the active ingredient that are suitable for nebulization and intrabronchial use, or aerosol compositions administered via an aerosol unit dispensing metered doses.
  • Suitable liquid compositions comprise the active ingredient in an aqueous, pharmaceutically acceptable inhalant solvent such as isotonic saline or bacteriostatic water.
  • the solutions are administered by means of a pump or squeeze-actuated nebulized spray dispenser, or by any other conventional means for causing or enabling the requisite dosage amount of the liquid composition to be inhaled into the patient's lungs.
  • Suitable Formulations wherein the carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.
  • Compositions suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by at least partially dispersing the active in one or more lipophilic bases and then shaping the mixture.
  • Pharmaceutical compositions may be formulated as sustained release formulations such as a capsule that creates a slow release of active following administration.
  • Such formulations may generally be prepared using well-known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Carriers for use within such formulations are biocompatible, and may also be biodegradable.
  • the formulation provides a relatively constant level of active release.
  • the amount of active contained within a sustained release formulation depends upon, for example, the site of implantation, the rate and expected duration of release and the nature of the condition to be treated.
  • One skilled in the art can readily select the proper form and route of administration depending on the particular characteristics of the compound selected, the disease or condition to be treated, the stage of the disease or condition, and other relevant circumstances. It will be understood, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, number of doses, and rate of excretion, drug combination (i.e.
  • a therapeutically effective amount generally refers to an amount of one or more active ingredients of the invention that (i) treats the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more sign or symptoms of the particular disease, condition, or disorder, or (iii) delays the onset of one or more sign or symptoms of the particular disease, condition, or disorder described herein.
  • a therapeutically effective dosage is formulated to contain a concentration (by weight) of at least about 0.1% up to about 50% or more, and all combinations and sub-combinations of ranges therein.
  • compositions can be formulated to contain one or more actives described herein in a concentration of from about 0.1 to less than about 50%, for example, about 49, 48, 47, 46, 45, 44, 43, 42, 41 or 40%, with concentrations of from greater than about 0.1%, for example, about 0.2, 0.3, 0.4 or 0.5%, to less than about 40%, for example, about 39, 38, 37, 36, 35, 34, 33, 32, 31 or 30%.
  • compositions may contain from about 0.5% to less than about 30%, for example, about 29, 28, 27, 26, 25, 25, 24, 23, 22, 21 or 20%, with concentrations of from greater than about 0.5%, for example, about 0.6, 0.7, 0.8, 0.9 or 1%, to less than about 20%, for example, about 19, 18, 17, 16, 15, 14, 13, 12, 11 or 10%.
  • the compositions can contain from greater than about 1% for example, about 2%, to less than about 10%, for example about 9 or 8%, including concentrations of greater than about 2%, for example, about 3 or 4%, to less than about 8%, for example, about 7 or 6%.
  • the active agent can, for example, be present in a concentration of about 5%.
  • the pharmaceutical composition comprises a compound according to any one of the herein disclosed embodiments, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, an additional therapeutic agent, and a pharmaceutically acceptable excipient.
  • the additional agent may be any suitable agent described herein.
  • the additional agent is a psychoactive drug, including those described herein.
  • the additional agent is useful for treatment of a disease, disorder or condition by activation of a serotonin receptor, including those described herein.
  • the additional agent is selected from any one of the following, including those described herein: an agent for a mental illness and/or a neuropsychiatric condition; an agent for psychosis and/or psychotic symptoms; an agent for attention deficit hyperactivity disorder and/or attention deficit disorder; an agent for dementia and/or Alzheimer’s disease; and an agent for an addiction disorder.
  • the present disclosure also provides methods of delivering to a subject in need thereof a compound of formula (I) or a composition (e.g., an effective amount of the compound or composition) of the present disclosure.
  • the present disclosure provides methods of treating a disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount (e.g., therapeutically effective amount) of a compound or composition (e.g., pharmaceutical composition) of the present disclosure.
  • the present disclosure provides methods of preventing a disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount (e.g., therapeutically effective amount) of a compound of formula (I) or composition (e.g., pharmaceutical composition) of the present disclosure.
  • a method e.g., method of delivering an active agent to a subject in need thereof, method of treating a disease in a subject in need thereof, method of preventing a disease in a subject in need thereof
  • uses of the compounds of formula (I) or compositions of the present disclosure in a method e.g., method of delivering an active agent to a subject in need thereof, method of treating a disease in a subject in need thereof, method of preventing a disease in a subject in need thereof
  • the effective amount is effective in treating the disease.
  • the effective amount is effective in preventing the disease.
  • the present disclosure provides a method of treating a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein.
  • the present disclosure provides a method of preventing a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein.
  • the present disclosure provides method of treating a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein, in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor.
  • the other known agents useful for treatment of a disease, disorder or condition by activation of a serotonin receptor may be any suitable agents known in the art, including those described herein.
  • the present disclosure provides method of preventing a disease, disorder or condition by activation of a serotonin receptor, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein, in combination with another known agent useful for prevention of a disease, disorder or condition by activation of a serotonin receptor.
  • the serotonin receptor is 5-HT2A.
  • the serotonin receptor is one or both of 5-HT2A and 5- HT2C. Additionally, or alternatively, in some embodiments, the serotonin receptor is not 5-HT2B.
  • the compound of formula (I) of the present disclosure is selective towards the 5-HT2A receptor over one or both of the 5-HT2C receptor and the 5-HT2B receptor, preferably over the 5-HT2B receptor. In some embodiments, the compound of formula (I) is selective towards the 5-HT2C receptor over one or both of the 5-HT2A receptor and the 5-HT2B receptor, preferably over the 5-HT2B receptor. In some embodiments, the compound of formula (I) is selective toward the 5-HT2A receptor and 5-HT2C receptor over the 5-HT2B receptor.
  • the compound of formula (I) of the present disclosure exhibits an EC50 value for the 5-HT2A receptor of less than about 1 mM, less than about 100 ⁇ M, less than about 10 ⁇ M, less than about 1 ⁇ M, or less than about 100 nM, or less than about 10 nM, as determined by an assay described herein, for example an assay of calcium flux activity such as measuring changes in intracellular calcium.
  • the compound of formula (I) exhibits an EC50 for the 5-HT2A receptor of less than about 1 mM, less than about 900 ⁇ M, less than about 800 ⁇ M, less than about 700 ⁇ M, less than about 600 ⁇ M, less than about 500 ⁇ M, less than about 400 ⁇ M, less than about 300 ⁇ M, less than about 200 ⁇ M, less than about 100 ⁇ M, less than about 90 ⁇ M, less than about 80 ⁇ M, less than about 70 ⁇ M, less than about 60 ⁇ M, less than about 50 ⁇ M, less than about 40 ⁇ M, less than about 30 ⁇ M, less than about 20 ⁇ M, less than about 10 ⁇ M, less than about 9 ⁇ M, less than about 8 ⁇ M, less than about 7 ⁇ M, less than about 6 ⁇ M, less than about 5 ⁇ M, less than about 4 ⁇ M, less than about 3 ⁇ M, less than about 2 ⁇ M, less than about 1 ⁇ M, less than about
  • the compound of formula (I) of the present disclosure exhibits an EC50 value for the 5-HT2C receptor of less than about 1 mM, less than about 100 ⁇ M, less than about 10 ⁇ M, less than about 1 ⁇ M, or less than about 100 nM, or less than about 10 nM, as determined by an assay described herein, for example an assay of calcium flux activity such as measuring changes in intracellular calcium.
  • the compound of formula (I) exhibits an EC50 for the 5-HT2C receptor of less than about 1 mM, less than about 900 ⁇ M, less than about 800 ⁇ M, less than about 700 ⁇ M, less than about 600 ⁇ M, less than about 500 ⁇ M, less than about 400 ⁇ M, less than about 300 ⁇ M, less than about 200 ⁇ M, less than about 100 ⁇ M, less than about 90 ⁇ M, less than about 80 ⁇ M, less than about 70 ⁇ M, less than about 60 ⁇ M, less than about 50 ⁇ M, less than about 40 ⁇ M, less than about 30 ⁇ M, less than about 20 ⁇ M, less than about 10 ⁇ M, less than about 9 ⁇ M, less than about 8 ⁇ M, less than about 7 ⁇ M, less than about 6 ⁇ M, less than about 5 ⁇ M, less than about 4 ⁇ M, less than about 3 ⁇ M, less than about 2 ⁇ M, less than about 1 ⁇ M, less than about
  • the compound of formula (I) of the present disclosure exhibits an EC50 value for the 5-HT2B receptor of greater than about 1 ⁇ M, greater than about 10 ⁇ M, or greater than about 100 ⁇ M, as determined by an assay described herein, for example an assay of calcium flux activity such as measuring changes in intracellular calcium.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness or a neuropsychiatric condition.
  • the present application also includes a method of treating a mental illness or a neuropsychiatric condition comprising administering to a subject in need thereof a compound of formula (I) or a composition as described herein.
  • the present application also includes a use of a compound of formula (I) of the present disclosure for treatment of a mental illness or a neuropsychiatric condition, as well as a use of a compound of formula (I) of the present disclosure for the preparation of a medicament for treatment of a mental illness or a neuropsychiatric condition.
  • the application further includes a compound of formula (I) of the present disclosure for use in treating a mental illness or a neuropsychiatric condition.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is a mental illness or a neuropsychiatric condition and compound of formula (I) of the present disclosure is administered in combination with one or more additional agents for a mental illness or a neuropsychiatric condition.
  • the one or more additional agents for a mental illness or a neuropsychiatric condition may be any suitable agents known in the art, including those described herein.
  • the additional agents for a mental illness or a neuropsychiatric condition is selected from antipsychotics, including typical antipsychotics and atypical antipsychotics; antidepressants including selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants and monoamine oxidase inhibitors (MAOIs) (e.g.
  • bupropion anti-anxiety medication including benzodiazepines such as alprazolam; agents for an addiction disorder such as alcohol addiction (e.g., disulfiram), nicotine dependence (e.g., varenicline) and opioid use disorder (e.g., methadone, buprenorphine, buprenorphine-naloxone and buprenorphine long-acting injection); mood stabilizers such as lithium and anticonvulsants such carbamazepine, divalproex (valproic acid), lamotrigine, gabapentin and topiramate.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is neurodegeneration.
  • the present application also includes a method of treating neurodegeneration comprising administering to a subject in need thereof a compound of formula (I) or a composition as described herein.
  • the present application also includes a use of a compound of formula (I) of the present disclosure for treatment of neurodegeneration, as well as a use of a compound of formula (I) of the present disclosure for the preparation of a medicament for treatment neurodegeneration.
  • the application further includes a compound of formula (I) of the present disclosure for use in treating neurodegeneration.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is reduced brain- derived neurotrophic factor (BDNF), mammalian target of rapamycin (mTOR) activation and/or inflammation.
  • BDNF brain- derived neurotrophic factor
  • mTOR mammalian target of rapamycin
  • the disease, disorder or condition that is treated by activation of a serotonin receptor comprises cognitive impairment; ischemia including stroke; neurodegeneration; refractory substance use disorders; sleep disorders; pain, such as social pain, acute pain, cancer pain, chronic pain, breakthrough pain, bone pain, soft tissue pain, nerve pain, referred pain, phantom pain, neuropathic pain, cluster headaches and migraine; obesity and eating disorders; epilepsies and seizure disorders; neuronal cell death; excitotoxic cell death; or a combination thereof.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms.
  • the present application also includes a method of treating psychosis or psychotic symptoms comprising administering to a subject in need thereof a compound of formula (I) or a composition as described herein.
  • the present application also includes a use of a compound of formula (I) of the present disclosure for treatment of psychosis or psychotic symptoms, as well as a use of a compound of formula (I) of the present disclosure for the preparation of a medicament for treatment of psychosis or psychotic symptoms.
  • the application further includes a compound of formula (I) of the present disclosure for use in treating psychosis or psychotic symptoms.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is psychosis or psychotic symptoms and the the compound of formula (I) of the present disclosure is administered in combination with one or more additional agents for psychosis or psychotic symptoms.
  • the one or more additional agents for psychosis or psychotic symptoms may be any suitable agents known in the art, including those described herein.
  • the additional agents for psychosis or psychotic symptoms are selected typical antipsychotics and atypical antipsychotics.
  • the typical antipsychotics may be selected from acepromazine, acetophenazine, benperidol, bromperidol, butaperazine, carfenazine, chlorproethazine, chlorpromazine, chlorprothixene, clopenthixol, cyamemazine, dixyrazine, droperidol, fluanisone, flupentixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, lenperone, loxapine, mesoridazine, metitepine, molindone, moperone, oxypertine, oxyprotepine, penfluridol, perazine, periciazine, perphenazine, pimozide, pipamperone, piperacetazine, pipotiazine, prochlorperazine, promazine, prothipendyl, spiperone, s
  • the atypical antipsychotics may be selected from amoxapine, amisulpride, aripiprazole, asenapine, blonanserin, brexpiprazole, cariprazine, carpipramine, clocapramine, clorotepine, clotiapine, clozapine, iloperidone, levosulpiride, lurasidone, melperone, mosapramine, nemonapride, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, reserpine, risperidone, sertindole, sulpiride, sultopride, tiapride, veralipride, ziprasidone and zotepine, and combinations thereof.
  • administering to said subject in need thereof a therapeutically effective amount of the compound of formula (I) of the present disclosure does not result in a worsening of psychosis or psychotic symptoms such as, but not limited to, hallucinations and delusions.
  • administering to said subject in need thereof a therapeutically effective amount of the compound of formula (I) results in an improvement of psychosis or psychotic symptoms such as, but not limited to, hallucinations and delusions.
  • administering to said subject in need thereof a therapeutically effective amount of the compounds of formula (I) results in an improvement of psychosis or psychotic symptoms.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition.
  • CNS central nervous system
  • the present application also includes a method of treating a CNS disease, disorder or condition and/or a neurological disease, disorder or condition comprising administering a therapeutically effective amount of compound of formula (I) or a composition of the present disclosure to a subject in need thereof.
  • the present application also includes a use of compound of formula (I) of the present disclosure for treatment a CNS disease, disorder or condition and/or a neurological disease, disorder or condition, as well as a use of compound of formula (I) of the present disclosure for the preparation of a medicament for treatment of a CNS disease, disorder or condition and/or a neurological disease, disorder or condition.
  • the application further includes a compound of formula (I) of the present disclosure of the application for use in treating a CNS disease, disorder or condition and/or a neurological disease, disorder or condition.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition and the compound of formula (I) of the present disclosure is administered in combination with one or more additional agents for a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition.
  • the one or more additional agents for a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition may be any suitable agents known in the art, including those described herein.
  • the additional agents for a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition are selected from lithium, olanzapine, quetiapine, risperidone, ariprazole, ziprasidone, clozapine, divalproex sodium, lamotrigine, valproic acid, carbamazepine, topiramate, levomilnacipran, duloxetine, venlafaxine, citalopram, fluvoxamine, escitalopram, fluoxetine, paroxetine, sertraline, clomipramine, amitriptyline, desipramine, imipramine, nortriptyline, phenelzine, tranylcypromine, diazepam, alprazolam, clonazepam, or any combination thereof.
  • CNS central nervous system
  • Non limiting examples of standard of care therapy for depression are sertraline, fluoxetine, escitalopram, venlafaxine, or aripiprazole.
  • Non-limiting examples of standard of care therapy for depression are citralopram, escitalopram, fluoxetine, paroxetine, diazepam, or sertraline.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is selected from attention deficit hyperactivity disorder and attention deficit disorder and a combination thereof.
  • the present application also includes a method of treating attention deficit hyperactivity disorder and/or attention deficit disorder comprising administering to a subject in need thereof a compound of formula (I) or a composition as described herein.
  • the present application also includes a use of a compound of formula (I) of the present disclosure for treatment of attention deficit hyperactivity disorder and/or attention deficit disorder, as well as a use of a compound of formula (I) of the present disclosure for the preparation of a medicament for treatment of attention deficit hyperactivity disorder and/or attention deficit disorder.
  • the application further includes a compound of formula (I) of the present disclosure for use in treating attention deficit hyperactivity disorder and/or attention deficit disorder.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof and the compound of formula (I) of the present disclosure is administered in combination with one or more additional agents for attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof.
  • the one or more additional agents for attention deficit hyperactivity disorder and/or attention deficit disorder may be any suitable agents known in the art, including those described herein.
  • the additional agents for attention deficit hyperactivity disorder and/or attention deficit disorder and a combination thereof are selected from methylphenidate, dexamphetamine, lisdexamfetine, atomoxetine and amphetamine and a combination thereof.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is selected from dementia and Alzheimer’s disease and a combination thereof. Accordingly, the present application also includes a method of treating dementia and/or Alzheimer’s disease comprising administering to a subject in need thereof a compound of formula (I) or a composition as described herein.
  • the present application also includes a use of a compound of formula (I) of the present disclosure for treatment of dementia and/or Alzheimer’s disease, as well as a use of a compound of formula (I) of the present disclosure for the preparation of a medicament for treatment of dementia and/or Alzheimer’s disease.
  • the application further includes a compound of formula (I) of the present disclosure for use in treating dementia and/or Alzheimer’s disease.
  • the disease, disorder or condition that is treated by activation of a serotonin receptor is dementia or Alzheimer’s disease and the compound of formula (I) of the present disclosure is administered in combination with one or more additional agents for dementia or Alzheimer’s disease.
  • the one or more additional agents for dementia or Alzheimer’s disease may be any suitable agents known in the art, including those described herein.
  • the additional agents for dementia and Alzheimer’s disease are selected from acetylcholinesterase inhibitors, NMDA antagonists and nicotinic agonists.
  • the acetylcholinesterase inhibitors may be selected from donepezil, galantamine, rivastigmine, and phenserine, and combinations thereof.
  • the NMDA antagonists may be selected from MK-801, ketamine, phencyclidine, and memantine, and combinations thereof.
  • the nicotinic agonists may be selected from nicotine, nicotinic acid, nicotinic alpha7 agonists, or alpha2 beta4 agonists or a combination thereof.
  • the present disclosure provides a method of treating a mental illness, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein.
  • the present disclosure provides a method of preventing a mental illness, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein.
  • the mental illness may be a neuropsychiatric condition.
  • the mental illness is selected from anxiety disorders such as generalized anxiety disorder, panic disorder, social anxiety disorder and specific phobias; depression such as, hopelessness, loss of pleasure, fatigue and suicidal thoughts; mood disorders, such as depression, bipolar disorder, cancer-related depression, anxiety and cyclothymic disorder; psychotic disorders, such as hallucinations, delusions, mania, schizophrenia, schizoaffective disorder, schizophreniform Disorder; impulse control and addiction disorders, such as pyromania (starting fires), kleptomania (stealing) and compulsive gambling; alcohol addiction; drug addiction, such as opioid addiction/dependence, nicotine dependence, cocaine dependence, marijuana abuse and so on; smoking cessation; personality disorders, such as antisocial personality disorder, aggression, obsessive-compulsive personality disorder and paranoid personality disorder; obsessive-compulsive disorder (OCD), such as thoughts or fears that cause a subject to perform certain rituals or routines; post- traumatic stress disorder (PTSD); stress response syndrome
  • anxiety disorders
  • the mental illness is selected from hallucinations and delusions and a combination thereof.
  • the hallucinations may be selected from visual hallucinations, auditory hallucinations, olfactory hallucinations, gustatory hallucinations, tactile hallucinations, proprioceptive hallucinations, equilibrioceptive hallucinations, nociceptive hallucinations, thermoceptive hallucinations and chronoceptive hallucinations, and a combination thereof.
  • the present disclosure provides a method for treating a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein.
  • the present disclosure provides a method for preventing a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition, the method comprising administering to a subject in need thereof a compound of formula (I) or a pharmaceutical composition as described herein.
  • the CNS disease, disorder or condition and/or neurological disease, disorder or condition is selected from neurological diseases including neurodevelopmental diseases and neurodegenerative diseases such as Alzheimer’s disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson’s disease and Parkinsonian related disorders such as Parkinson dementia, corticobasal degeneration, and supranuclear palsy; epilepsy; CNS trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington’s disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder and attention deficit disorders; restless leg syndrome; Tourette's syndrome; Tic disorder; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system including eating disorders such as anorexia
  • the present disclosure provides a method for increasing neuronal plasticity, the method comprising contacting a neuronal cell with a compound of formula (I) or a pharmaceutical composition as described herein, in an amount sufficient to increase neuronal plasticity of the neuronal cell.
  • Neuronal plasticity refers to the ability of the brain to change its structure and/or function continuously throughout a subject’s life. Examples of the changes to the brain include, but are not limited to, the ability to adapt or respond to internal and/or external stimuli, such as due to an injury, and the ability to produce new neurites, dendritic spines, and synapses.
  • Increasing neuronal plasticity includes, but is not limited to, promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendritogenesis, increasing dendritic arbor complexity, increasing dendritic spine density, and increasing excitatory synapsis in the brain.
  • increasing neuronal plasticity comprises promoting neuronal growth, promoting neuritogenesis, promoting synaptogenesis, promoting dendritogenesis, increasing dendritic arbor complexity, and increasing dendritic spine density.
  • increasing neuronal plasticity can treat neurodegenerative disorder, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, addiction, anxiety, post-traumatic stress disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder.
  • the present disclosure provides methods of treating weight, comprising administering an effective amount of a compound of the invention to a subject in need thereof.
  • Treatment of weight may include treating weight gain; weight loss; metabolic disorder; weight gain associated with pharmaceutical intervention; weight gain associated with a mental illness (including those described herein); eating disorders such as anorexia, bulimia, cachexia, etc.; eating behaviour; obesity; diabetes; insulin resistance; pre-diabetes; glucose intolerance; hyperlipidemia; and cardiovascular disease.
  • the present disclosure provides a method for increasing dendritic spine density, the method comprising contacting a neuronal cell with a compound of formula (I) or a pharmaceutical composition as described herein, in an amount sufficient to increase dendritic spine density of the neuronal cell.
  • the compound of formula (I) produces a maximum number of dendritic crossings with an increase of greater than 1.0 fold by a Sholl Analysis.
  • the present disclosure provides a method for activating a serotonin receptor in a cell, either in a biological sample or in a patient, comprising administering a compound of formula (I) as defined in any one of the herein disclosed embodiments to the cell.
  • the serotonin receptor may be a 5-HT receptor subtype, preferably one or both of 5-HT2A and 5-HT2C.
  • effective amounts vary according to factors such as the disease state, age, sex and/or weight of the subject or species.
  • the amount of a given compound or compounds that will correspond to an effective amount will vary depending upon factors, such as the given drug(s) or compound(s), the pharmaceutical formulation, the route of administration, the type of condition, disease or disorder, the identity of the subject being treated and the like, but can nevertheless be routinely determined by one skilled in the art.
  • the compounds of formula (I) of the present disclosure are administered one, two, three or four times a year.
  • the compounds of the present disclosure are administered at least once a week.
  • the compounds are administered to the subject from about one time per two weeks, three weeks or one month.
  • the compounds are administered about one time per week to about once daily.
  • the compounds are administered 1, 2, 3, 4, 5 or 6 times daily.
  • the length of the treatment period depends on a variety of factors, such as the severity of the disease, disorder or condition, the age of the subject, the concentration and/or the activity of the compounds of the application and/or a combination thereof.
  • the effective dosage of the compound used for the treatment may increase or decrease over the course of a particular treatment regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration is required.
  • the compounds are administered to the subject in an amount and for duration sufficient to treat the subject.
  • the compounds of the application are administered at doses that are hallucinogenic or psychotomimetic and taken in conjunction with psychotherapy or therapy and may occur once, twice, three, or four times a year.
  • the compounds are administered to the subject once daily, once every two days, once every 3 days, once a week, once every two weeks, once a month, once every two months, or once every three months at doses that are not hallucinogenic or psychotomimetic.
  • a compound of formula (I) of the present disclosure may be either used alone or in combination with other known agents useful for treating diseases, disorders or conditions by activation of a serotonin receptor, such as the compounds of the present disclosure.
  • a compound of formula (I) is administered contemporaneously with those agents.
  • "contemporaneous administration" of two substances to a subject means providing each of the two substances so that they are both active in the individual at the same time. The exact details of the administration will depend on the pharmacokinetics of the two substances in the presence of each other and can include administering the two substances within a few hours of each other, or even administering one substance within 24 hours of administration of the other, if the pharmacokinetics are suitable. Design of suitable dosing regimens is routine for one skilled in the art.
  • two substances will be administered substantially simultaneously, i.e., within minutes of each other, or in a single composition that contains both substances. It is a further embodiment of the present application that a combination of agents is administered to a subject in a non-contemporaneous fashion.
  • a compound of formula (I) of the present disclosure is administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present application provides a single unit dosage form comprising one or more compounds of formula (I) as described herein, an additional therapeutic agent and a pharmaceutically acceptable carrier.
  • the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that are devoid of clinically meaningful psychedelic/ psychotomimetic actions. In some embodiments, the compounds of the application are used or administered in an effective amount which comprises administration of doses or dosage regimens that provide clinical effects similar to those exhibited by a human plasma psilocin Cmax of 4 ng/mL or less and/or human 5-HT2A human CNS receptor occupancy of 40% or less or those exhibited by a human plasma psilocin Cmax of 1 ng/mL or less and/or human 5- HT2A human CNS receptor occupancy of 30% or less.
  • kits in another embodiment there is provided a kit or article of manufacture including one or more compounds, pharmaceutically acceptable salt, stereoisomer, solvate, metabolite, or polymorph, and/or pharmaceutical compositions as described above.
  • kits for use in a therapeutic application mentioned above including: a container holding one or more compounds, pharmaceutically acceptable salt, stereoisomer, solvate, metabolite, or polymorph and/or pharmaceutical compositions as described herein; a label or package insert with instructions for use.
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, “rt,” or “RT,” (typically a range of from about 18-25 °C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (typically, 4.5-30 mm Hg) with a bath temperature of up to 60 °C; the course of reactions was typically followed by thin layer chromatography (TLC); melting points are uncorrected; products exhibited satisfactory 1 H NMR and/or microanalytical data; and the following conventional abbreviations are also used: L (litres), mL (millilitres), mmol (millimoles), g (grams), mg (milligrams), min (minutes), and h (hours).
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, “rt,” or “RT,” (typically a range of from about 18-25 °C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (typically, 4.5-30 mm Hg) with a bath temperature of up to 60 °C; the course of reactions was typically followed by thin layer chromatography (TLC); melting points are uncorrected; products exhibited satisfactory 1 H NMR and/or microanalytical data; and the following conventional abbreviations are also used: L (litres), mL (millilitres), mmol (millimoles), g (grams), mg (milligrams), min (minutes), and h (hours).
  • Scheme 1 Compounds of general formula (I) can be synthesised from an appropriately substituted naphthaldehyde following the outlined sequence of steps in Scheme 1 or similar as one skilled in the art may utilise.
  • R n represents any of substituents R 4 to R 10 as defined herein for formula (I).
  • R n may be a substituent on any of the positions corresponding to R 4 to R 10 and will be limited by the appropriate definition depending on where it is positioned around the naphthyl core.
  • An appropriately substituted naphthaldehyde can be subjected to a Henry reaction to afford the corresponding nitroalkene which can be reduced to give compounds of general formula (I) wherein R 1 and R 2 are H.
  • Naphthaldehydes can undergo a one carbon homologation through a Wittig reaction to generate methoxyvinylnaphthalenes that under hydrolytic conditions garner the appropriate aldehyde.
  • Compounds of general formula (I) can be afforded via reductive amination with appropriately substituted amines (exemplified by, but not limited to, Example I-3, I-4, etc).
  • R n is a methoxy group
  • demethylation can be performed using boron tribromide to give the corresponding hydroxy compound (exemplified by, but not limited to, Example I-10, I- 11).
  • Scheme 3 In cases where the requisite naphthaldehyde is not commercially available, the starting naphthaldehydes can be accessed in numerous ways as one skilled in the art may be aware. Hydroxy and methoxy substituents are shown in scheme 3 as representative examples. Two of several exemplary methods utilised to synthesise exemplified compounds are provided. Appropriately halogenated hydroxynaphthalene starting reagents can be converted to the corresponding methyl ether before undergoing Bouveault aldehyde synthesis, involving metal-halogen exchange (lithiation or Grignard formation).
  • the subsequent organometallic intermediate can be quenched with DMF and subsequently hydrolysed to access the required naphthaldehydes.
  • hydroxy naphthoic acids can be simultaneously methylated and esterified followed by reduction to the primary alcohol which can be selectively oxidised to the aldehyde in numerous ways (Dess-Martin Periodinane, Pyridinium Chlorochromate etc).
  • Scheme 4 Compounds of general formula (I) can be synthesised from an appropriately substituted tetralone following the outlined sequence of steps in Scheme 4 or similar as one skilled in the art may utilise.
  • a 3,4-dihydronaphthalen-1(2H)-one with the appropriate aromatic substitution pattern can undergo a Wittig-Horner reaction to yield the intermediate 3,4-dihydronaphthalene ester which can be aromatised under oxidative conditions including using the oxidant 2,3-dichloro-5,6-dicyano-p- benzoquinone (DDQ) or by catalytic transfer hydrogenation to the corresponding 6,6- aromatic system.
  • DDQ 2,3-dichloro-5,6-dicyano-p- benzoquinone
  • Ester hydrolysis under basic conditions allows access to a carboxylic acid intermediate which can undergo condensation reactions with a variety of amide coupling reagents and the appropriately substituted amine component. Subjecting the resulting amides to reductive conditions allows accessed to the desired compounds of general formula (I) (exemplified by Examples I-44 to I-46). Scheme 4 Alternatively, the ester can be subjected to reductive conditions, such as LiBH4 or LiAlH4, to afford the corresponding alcohol.
  • reductive conditions such as LiBH4 or LiAlH4
  • the alcohol can be oxidised to the corresponding aldehyde for subsequent reductive alkylation or can be activated, such as by the formation of a methanesulfonate, to react with the appropriately substituted amine component, to access the desired compounds of general formula (I), as shown in Scheme 5, or similar as one skilled in the art may utilise.
  • Step 2 (E)-2-methoxy-1-(2-nitrovinyl)naphthalene (3)
  • a solution of 2-methoxy-1-naphthaldehyde (5 g, 26.9 mmol) and nitromethane (28.8 mL, 20 equiv., 537 mmol) was treated with NH4OAc (1.24 g, 16.1 mmol) and the resulting solution was stirred at 80 oC for 3 h.
  • the reaction was then diluted with abs. EtOH (50 mL) and H2O (10 mL) whilst still hot.
  • the resulting suspension was allowed to cool to RT and the yellow solid was collected by vacuum filtration which was identified as the title compound (5.7 g, 93%).
  • Step 3 2-(2-methoxynaphthalen-1-yl)ethan-1-amine (4)
  • An ice-cold solution of 2-methoxy-1-(2-nitroethenyl)naphthalene (5 g, 21.8 mmol) in anhydrous THF (100 mL) was treated portionwise with LiAlH4 (6.6 g, 174 mmol) at a rate that maintained a gentle effervescence.
  • the reaction was then heated to reflux for 3 h and the cooled reaction was diluted with THF (200 mL) and then quenched with cold H2O (6 mL), 15% aq. NaOH (6 mL), and H2O (20 mL).
  • Step 4 2-(2-methoxynaphthalen-1-yl)-N,N-dimethylethan-1-amine fumarate (I- 2 ⁇ fumarate)
  • 2-(2-methoxy-1-naphthyl)ethylamine 300 mg, 1.49 mmol
  • formaldehyde 37% w/w, 1.21 mL, 14.9 mmol
  • NaBH(OAc)3 1.5 g, 7.4 mmol
  • Example 2 Synthesis of N-ethyl-2-(2-methoxynaphthalen-1-yl)-N-methylethan-1- amine (I-3) Step 1: 2-methoxy-1-(2-methoxyvinyl)naphthalene (6) To an ice-cold solution of 2-methoxy-1-naphthaldehyde (5.0 g, 26.8 mmol) in anhydrous THF (50 mL) was added potassium tert-butoxide (9.0 g, 80.4 mmol) followed by (methoxymethyl)triphenyl phosphonium chloride (18.4 g, 53.6 mmol) under an atmosphere of nitrogen gas.
  • Step 2 2-(2-methoxynaphthalen-1-yl)acetaldehyde (7)
  • 6-methoxy-1-(2-methoxyvinyl)naphthalene 4.5 g, 21.0 mmol
  • THF 40 mL
  • 5 M aq. HCl 22.5 mL
  • the reaction mixture was then quenched with saturated aq. NaHCO 3 (80 mL) and extracted with 10% MeOH in DCM (150 mL x 3).
  • Step 3 N-ethyl-2-(2-methoxynaphthalen-1-yl)-N-methylethan-1-amine (I-3)
  • 2-(2-methoxynaphthalen-1-yl)acetaldehyde 900 mg, 4.5 mmol
  • DCE DCE
  • N-methylethanamine 780 mg, 13.5 mmol
  • the reaction was stirred for 30 min at this temperature, at which time the reaction mixture was cooled to 0 °C and treated portion wise with Na(OAc)3BH (1.7 g, 13.5 mmol).
  • the reaction mixture was allowed to stir for 16 h at RT before being poured into saturated aq.
  • Step 4 N-ethyl-2-(2-methoxynaphthalen-1-yl)-N-methylethan-1-amine fumarate (I- 3 ⁇ fumarate) N-ethyl-2-(2-methoxynaphthalen-1-yl)-N-methylethan-1-amine (70 mg, 0.29 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a light-brown solid (70 mg, 67%).
  • Example 3 Synthesis of 1-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol (I-10) Step 1: 1-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol fumarate (I-10 ⁇ fumarate) To a stirred solution of N-ethyl-2-(2-methoxynaphthalen-1-yl)-N-methylethan-1- amine (500 mg, 2.05 mmol) in CH 2 Cl 2 (5 mL) was added 1 M BBr3 in CH 2 Cl 2 (2.5 mL) at 0 °C under an atmosphere of nitrogen gas and the reaction was stirred at RT for 2 h.
  • Example 4 Synthesis of N-(2-(2-methoxynaphthalen-1-yl)ethyl)propan-2-amine (I- 77)
  • Step 1 N-(2-(2-methoxynaphthalen-1-yl)ethyl)propan-2-amine fumarate (I- 77 ⁇ fumarate)
  • acetone 0.15 mL, 2.0 mmol
  • NaBH(OAc)3 1.0 g, 4.97 mmol
  • the reaction was stirred at RT for 3 h and then quenched with water (10 mL), neutralised with saturated aq. Na2CO3, and then made more basic with 15% aq. NaOH (2 mL).
  • the mixture was diluted with CH 2 Cl 2 (20 mL) and the layers were separated.
  • the aqueous layer was further extracted with CHCl3:i-PrOH (20 mL x 3) and the combined organic layer was washed with brine (50 mL), then dried over anhydrous Na2SO4, filtered, and the filtrate concentrated in vacuo.
  • Example 5 Synthesis of N-(2-(2-methoxynaphthalen-1-yl)ethyl)-N-methylpropan- 2-amine (I-4) Step 1: N-(2-(2-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (I-4) To a solution of 2-(2-methoxy-1-naphthyl)ethylamine (1.0 g, 5.0 mmol) in ( CH 2 Cl) 2 (15 mL) was added acetone (0.74 mL, 9.94 mmol), followed by NaBH(OAc)3 (5.27 g, 24.8 mmol).
  • Example 6 Synthesis of 1-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol (I-11) Step 1: 1-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol fumarate (I-11 ⁇ fumarate) 1-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol (150 mg, 0.62 mmol) was synthesised following the same method as compound I-10, which was then formulated as the fumarate salt according to general procedure B which was isolated as an off- white solid (150 mg, 67%).
  • Example 7 Synthesis of 1-(2-(2-methoxynaphthalen-1-yl)ethyl)azetidine (I-6) Step 1: 1-(2-(2-methoxynaphthalen-1-yl)ethyl)azetidine fumarate (I-6 ⁇ fumarate) 1-(2-(2-methoxynaphthalen-1-yl)ethyl)azetidine (70 mg, 0.29 mmol) was synthesised following the same method as compound I-3, which was then formulated as the fumarate salt according to general procedure B which was isolated as a light-brown solid (60 mg, 55%).
  • Example 8 Synthesis of 1-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol (I-13) Step 1: 1-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol trifluoroacetate (I-13 ⁇ trifluoroacetate) 1-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol trifluoroacetate (80 mg, 0.23 mmol) was synthesised following the same method as compound I-10, with TFA used as a modifier in the mobile phase.
  • Example 9 Synthesis of 1-(2-(2-methoxynaphthalen-1-yl)ethyl)pyrrolidine (I-7) Step 1: 1-(2-(2-methoxynaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-7 ⁇ fumarate) 1-(2-(2-methoxynaphthalen-1-yl)ethyl)pyrrolidine (130 mg, 0.51 mmol) was synthesised following the same method as compound I-3, which was then formulated as the fumarate salt according to general procedure B which was isolated as a light-brown solid (110 mg, 50%).
  • Example 10 Synthesis of 1-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol (I-14)
  • Step 1 1-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol fumarate (I-14 ⁇ fumarate)
  • 1-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol (190 mg, 0.79 mmol) was synthesised following the same method as compound I-10, which was then formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (150 mg, 51%).
  • Example 11 Synthesis of N-ethyl-2-(2-fluoronaphthalen-1-yl)-N-methylethan-1- amine (I-61) Step 1: 2-fluoro-3,4-dihydronaphthalen-1(2H)-one (9) To a stirred solution of 3,4-dihydronaphthalen-1(2H)-one (10.0 g, 68.5 mmol) in MeOH (150 mL) was added Selectfluor (28.3 g, 82.0 mmol) and conc. aq. H2SO4 (0.3 mL) at RT.
  • reaction mixture was stirred at 50 oC for 16 h and then the cooled reaction was poured into water (200 mL) and extracted with EtOAc (200 mL x 2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduce pressure. The residue was purified by flash chromatography (SiO 2 , 0% to 4 % EtOAc in hexane) to afford the title compound as a yellow oil (6.0 g, 53%).
  • Step 2 Ethyl 2-(2-fluoro-3,4-dihydronaphthalen-1-yl)acetate (10) To a stirred solution of 2-fluoro-3,4-dihydronaphthalen-1(2H)-one (2.5 g, 15.24 mmol) in THF (7 mL) was added NaH (60% w/w in mineral oil, 0.8 g, 33.33 mmol) and ethyl 2-(diethoxyphosphoryl)acetate (2.5 g, 11.16 mmol) at 0 oC. The resulting reaction mixture was stirred at 70 °C for 16 h. before being quenched with water (200 mL) and extracted with EtOAc (200 mL x 2).
  • Step 3 Ethyl 2-(2-fluoronaphthalen-1-yl)acetate (11) To a stirred solution ethyl 2-(2-fluoro-3,4-dihydronaphthalen-1-yl)acetate (2.3 g, 9.83 mmol) in toluene (80.5 mL) was added DDQ (2.6 g, 11.79 mmol) at RT. The reaction mixture was stirred at 120 °C for 3 h before being filtered. The filtrate was diluted with EtOAc (200 mL) and washed with brine (100 mL) before being dried over anhydrous Na2SO4 and concentrated under reduce pressure.
  • Step 4 2-(2-fluoronaphthalen-1-yl)ethan-1-ol (12) To an ice-cold stirred solution of ethyl 2-(2-fluoronaphthalen-1-yl)acetate (2.0 g, 8.62 mmol) in THF (20 mL) was added LiAlH4 (0.47 g, 12.92 mmol) in portions. The reaction mixture was then stirred at RT for 1 h before the reaction was quenched by slow addition into water (200 mL).
  • Step 5 2-(2-fluoronaphthalen-1-yl)ethyl methanesulfonate (13)
  • 2-(2-fluoronaphthalen-1-yl)ethan-1-ol 1.8 g, 9.47 mmol
  • CH 2 Cl 2 18 mL
  • TEA 2.8 g, 27.72 mmol
  • MsCl 1.6 g, 14.4 mmol
  • the resulting reaction mixture was stirred at 0 oC for 2 h before being quenched with water (100 mL) and extracted with EtOAc (100 mL x 2).
  • Step 6 N-ethyl-2-(2-fluoronaphthalen-1-yl)-N-methylethan-1-amine (I-61) To a stirred solution 2-(2-fluoronaphthalen-1-yl)ethyl methanesulfonate (200 mg, 0.74 mmol) in MeCN (2 mL) was added N-methylethanamine (220 mg, 3.73 mmol) and K 2 CO 3 (510 g, 3.73 mmol) at RT.
  • Step 7 N-ethyl-2-(2-fluoronaphthalen-1-yl)-N-methylethan-1-amine fumarate (I- 61 ⁇ fumarate) N-ethyl-2-(2-fluoronaphthalen-1-yl)-N-methylethan-1-amine (75 mg, 0.32 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a white solid (95 mg, 86%).
  • Example 12 Synthesis of N-(2-(2-fluoronaphthalen-1-yl)ethyl)-N-methylpropan-2- amine (I-62)
  • Step 1 N-(2-(2-fluoronaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (I-62)
  • 2-(2-fluoronaphthalen-1-yl)ethyl methanesulfonate 450 mg, 1.67 mmol
  • MeCN 5 mL
  • K2CO3 1.15 g, 8.38 mmol
  • reaction mixture was stirred at 80 °C for 16 h before being quenched with water (35 mL) and extracted with EtOAc (30 mL x 2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduce pressure. The residue was purified by reverse phase column chromatography (product eluted at 59% MeCN in water) to afford the title compound as a yellow resin (90 mg, 22%).
  • Step 2 N-(2-(2-fluoronaphthalen-1-yl)ethyl)-N-methylpropan-2-amine fumarate (I- 62 ⁇ fumarate) N-(2-(2-fluoronaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (90 mg, 0.37 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a light-brown solid (80 mg, 67%).
  • Example 13 Synthesis of 1-(2-(2-fluoronaphthalen-1-yl)ethyl)azetidine (I-65)
  • Step 1 1-(2-(2-fluoronaphthalen-1-yl)ethyl)azetidine (I-65)
  • 2-(2-fluoronaphthalen-1-yl)ethyl methanesulfonate (200 mg, 0.75 mmol) in MeCN (5 mL) was added azetidine (210 mg, 3.72 mmol) and K2CO3 (510 mg, 3.72 mmol) at RT.
  • reaction mixture was stirred at 80 oC for 16 h before being quenched with water (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduce pressure. The residue was purified by reverse phase column chromatography (product eluted at 58 % MeCN in water) to afford the title compound as a brown resin (130 mg, 76%).
  • Step 2 1-(2-(2-fluoronaphthalen-1-yl)ethyl)azetidine fumarate (I-65 ⁇ fumarate) 1-(2-(2-fluoronaphthalen-1-yl)ethyl)azetidine (130 mg, 0.56 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (220 mg, quant.).
  • Example 14 Synthesis of 1-(2-(2-fluoronaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-66) Step 1: 1-(2-(2-fluoronaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-66) To a stirred solution 2-(2-fluoronaphthalen-1-yl)ethyl methanesulfonate (450 mg, 1.68 mmol) in MeCN (10 mL) was added pyrrolidine (590 mg, 8.39 mmol) and K2CO3 (1.15 g, 8.39 mmol) at RT.
  • reaction mixture was stirred at 80 oC for 16 h before being quenched with water (60 mL) and extracted with EtOAc (45 mL x 3). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduce pressure. The residue was purified by reverse phase column chromatography (product eluted at 72% MeCN in water) to afford the title compound as a yellow resin (200 mg, 44%).
  • Step 2 1-(2-(2-fluoronaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-66 ⁇ fumarate) 1-(2-(2-fluoronaphthalen-1-yl)ethyl)pyrrolidine (80 mg, 0.32 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (95 mg, 81%).
  • Example 15 Synthesis of N-ethyl-2-(3-methoxynaphthalen-1-yl)-N-methylethan-1- amine (I-17)
  • Step 1 1-bromo-3-methoxynaphthalene
  • 4-bromonaphthalen-2-ol 5.0 g, 22.42 mmol, 1.0 eq
  • DMF 50 mL
  • NaH 3 g, 60% w/w dispersion in mineral oil, 40.3 mmol
  • the reaction mass was stirred for 30 min at this temperature followed by the addition of MeI (12.7 g, 89.7 mmol).
  • Step 2 3-methoxy-1-naphthaldehyde (16) To a stirred solution of 1-bromo-3-methoxynaphthalene (5.0 g, 21.09 mmol) in dry THF (50 mL) at -78 °C was added dropwise a solution of n-BuLi (2.5M in THF, 25 mL, 42.19 mmol) over 15 minutes (80 mL) under an atmosphere of nitrogen gas and maintained at this temperature for a further 2 h. The reaction mass was then treated with DMF (2.5 mL, 52.74 mmol) dropwise.
  • DMF 2.5 mL, 52.74 mmol
  • Step 3 3-methoxy-1-(2-methoxyvinyl) naphthalene (17)
  • KOtBu 9.0 g, 80.6 mmol
  • dry THF 50 mL
  • N2 gas nitrogen trioxide
  • the reaction mixture was then cooled to 0 °C and treated with 3-methoxy-1-naphthaldehyde (5.0 g, 26.88 mmol) in portions, warmed to RT and stirring continued for a further 3 h.
  • Step 5 N-ethyl-2-(3-methoxynaphthalen-1-yl)-N-methylethan-1-amine (I-17)
  • 2-(3-methoxynaphthalen-1-yl)acetaldehyde 1.5 g, 7.5 mmol
  • DCE 10 mL
  • N-methylethanamine 1.3 g, 22.5 mmol
  • the reaction was stirred for 30 min at this temperature, at which time the reaction mixture was cooled to 0 °C and treated portion wise with Na(OAc)3BH (2.8 g, 22.5 mmol).
  • the reaction mixture was allowed to stir for 16 h at RT before being poured into saturated aq.
  • Example 16 Synthesis of 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol (I-25)
  • Step 1 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol trifluoroacetate (I- 25 ⁇ trifluoroacetate)
  • N-ethyl-2-(3-methoxynaphthalen-1-yl)-N-methylethan-1- amine 1.0 g, 4.11 mmol
  • CH 2 Cl 2 10 mL
  • 1 M BBr3 in CH 2 Cl 2 5.0 mL
  • Step 2 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol fumarate (I-25 ⁇ fumarate) 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol trifluoroacetate (64 mg, 0.19 mmol) was reformulated as the fumarate salt according to general procedure B which was isolated as a white solid (62 mg, 95%).
  • LCMS (Condition B): tR (1.072 min) m/z 230.2 [M+H] + ; 1 H NMR (400 MHz, DMSO-d 6 ): ⁇ 9.80 (br.
  • Example 17 Synthesis of N-(2-(3-methoxynaphthalen-1-yl)ethyl)-N-methylpropan- 2-amine (I-18)
  • Step 1 N-(2-(3-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (I-18)
  • 2-(3-methoxynaphthalen-1-yl)acetaldehyde 900 mg, 4.5 mmol
  • N-methylpropan-2-amine (0.98 g, 13.5 mmol
  • 1-2 drops of acetic acid at RT under an atmosphere of nitrogen gas.
  • Step 2 N-(2-(3-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (I- 18 ⁇ fumarate) N-(2-(3-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (70 mg, 0.27 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a white solid (80 mg, 79%).
  • Example 18 Synthesis of 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol (I- 26)
  • Step 1 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol trifluoroacetate (I- 26 ⁇ trifluoroacetate)
  • N-(2-(3-methoxynaphthalen-1-yl)ethyl)-N-methylpropan- 2-amine 670 mg, 2.62 mmol
  • CH 2 Cl 2 6.75 mL
  • Step 2 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol fumarate (I-26 ⁇ fumarate) 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol trifluoroacetate (100 mg, 0.28 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (100 mg, quant.).
  • Example 19 Synthesis of 1-(2-(3-methoxynaphthalen-1-yl)ethyl)azetidine (I-20)
  • Step 1 1-(2-(3-methoxynaphthalen-1-yl)ethyl)azetidine (I-20)
  • 2-(3-methoxynaphthalen-1-yl)acetaldehyde 1.0 g, 4.99 mmol
  • DCE 10 mL
  • azetidine 1.0 mL, 15.0 mmol
  • NaBH(OAc)3 3.18 g, 15.0 mmol
  • Step 2 1-(2-(3-methoxynaphthalen-1-yl)ethyl)azetidine fumarate (I-20 ⁇ fumarate) 1-(2-(3-methoxynaphthalen-1-yl)ethyl)azetidine (140 mg, 0.58 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (140 mg, 70%).
  • Example 20 Synthesis of 4-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol (I-28) Step 1: 4-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol (I-28) 4-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol (4 mg, 0.02 mmol) was synthesized analogously to I-10.
  • Example 21 Synthesis of 1-(2-(3-methoxynaphthalen-1-yl)ethyl)pyrrolidine (I-21)
  • Step 1 1-(2-(3-methoxynaphthalen-1-yl)ethyl)pyrrolidine trifluoroacetate (I- 21 ⁇ trifluoroacetate)
  • 2-(3-methoxynaphthalen-1-yl) acetaldehyde 500 mg, 2.50 mmol
  • DCE 5 mL
  • pyrrolidine pyrrolidine (0.63 mL, 7.50 mmol
  • Step 2 1-(2-(3-methoxynaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-21 ⁇ fumarate) 1-(2-(3-methoxynaphthalen-1-yl)ethyl)pyrrolidine trifluoroacetate (70 mg, 0.19 mmol) was reformulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (64 mg, 94%).
  • Example 22 Synthesis of 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol (I-29) Step 1: 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol trifluoroacetate (I-29 ⁇ trifluoroacetate) To a stirred solution of 1-(2-(3-methoxynaphthalen-1-yl)ethyl)pyrrolidine (470 mg, 1.84 mmol) in CH 2 Cl 2 (4.7 mL) was added 1 M BBr3 in CH 2 Cl 2 (2.35 mL) at 0 °C under an atmosphere of nitrogen gas and the reaction mixture was stirred at 0 °C for 2 h.
  • Step 2 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol fumarate (I-29 ⁇ fumarate) 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol trifluoroacetate (160 mg, 0.45 mmol) was reformulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (100 mg, 88%).
  • Example 23 Synthesis of 2-(4-methoxynaphthalen-1-yl)-N,N-dimethylethan-1- amine (I-68) Step 1: 1-methoxy-4-(2-nitrovinyl)naphthalene (20) To a solution of 4-methoxy-1-naphthaldehyde (4.05 g, 21.7 mmol) in nitromethane (50 mL, 934 mmol) was added ammonium acetate (4.53 g, 58.7 mmol) and the mixture was stirred at 80 °C for 3 h under a N2 atmosphere. After cooling, the reaction was diluted with H2O (80 mL) and left to stand at 0 °C overnight.
  • H2O 80 mL
  • Step 2 2-(4-methoxynaphthalen-1-yl)ethan-1-amine (21)
  • a solution of 1-methoxy-4-(2-nitrovinyl)naphthalene (1.42 g, 6.19 mmol) in anhydrous THF (30 mL) was cooled to 0 °C and LiAlH4 (943 mg, 24.8 mmol) was added portionwise under nitrogen atmosphere.
  • the mixture was refluxed for 3 h and then, after cooling, was quenched with cold H2O (1 mL), then 15% aq. NaOH (1 mL), then H2O (3 mL).
  • the resulting mixture was filtered through a pad of celite and the filter cake washed with THF (3 x 25 mL).
  • Step 3 2-(4-methoxynaphthalen-1-yl)-N,N-dimethylethan-1-amine (I-68) To a solution of 2-(4-methoxynaphthalen-1-yl)ethan-1-amine (141 mg, 0.70 mmol) in MeOH (2.0 mL) at 0 °C was added 40% formaldehyde (158 mg, 2.10 mmol) and NaCNBH 3 (176 mg, 2.80 mmol) and the mixture was stirred at room temperature for 3 hours. The mixture was then concentrated under a stream of nitrogen and treated with 1 M NaOH (3.0 mL) and extracted with EtOAc (3 x 10 mL).
  • Step 4 2-(4-methoxynaphthalen-1-yl)-N,N-dimethylethan-1-amine fumarate (I- 68 ⁇ fumarate) 2-(4-methoxynaphthalen-1-yl)-N,N-dimethylethan-1-amine was formulated as the fumarate salt according to general procedure B and was isolated as white crystals (37 mg, 22%).
  • Example 24 Synthesis of 4-(2-(dimethylamino)ethyl)naphthalen-1-ol (I-69) Step 1: 4-(2-(dimethylamino)ethyl)naphthalen-1-ol (I-69) To a solution of 2-(4-methoxynaphthalen-1-yl)-N,N-dimethylethan-1-amine (47 mg, 0.20 mmol) in CH 2 Cl 2 (3.0 mL) at 0 °C was added BBr3 (0.4 mL, 4.28 mmol) and the mixture was stirred at 0 °C for 1.5 hours.
  • the reaction was diluted with CH 2 Cl 2 (20 mL), cooled to 0 °C, and treated with saturated aq. Na2CO3 (2.0 mL) dropwise followed by 2.5 M aq. NaOH (4.0 mL).
  • the CH 2 Cl 2 was evaporated under a stream of nitrogen gas and the remaining aqueous phase was extracted with EtOAc (3 x 20 mL).
  • the combined organics were washed with brine (15 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure.
  • Step 2 4-(2-(dimethylamino)ethyl)naphthalen-1-ol fumarate (I-69 ⁇ fumarate) 4-(2-(dimethylamino)ethyl)naphthalen-1-ol (28 mg, 0.13 mmol) was formulated as the fumarate salt according to general procedure B and was isolated as white crystals (22 mg, 51%).
  • Example 25 Synthesis of N-ethyl-2-(4-methoxynaphthalen-1-yl)-N-methylethan-1- amine (I-78)
  • Step 1 1-methoxy-4-(2-methoxyvinyl)naphthalene (22)
  • KOtBu KOtBu
  • Step 2 2-(4-methoxynaphthalen-1-yl)acetaldehyde (23)
  • the reaction mixture was cooled in an ice bath and quenched with NaHCO 3 .
  • Et2O 40 mL was added and the organic layer was separated, dried over anhydrous Na2SO4 and concentrated under reduced pressure.
  • Step 3 N-ethyl-2-(4-methoxynaphthalen-1-yl)-N-methylethan-1-amine (I-78)
  • a stirred mixture of N-methylethylamine (0.21 mL, 2.50 mmol) in CH 2 Cl 2 (5 mL) at 0 °C was treated with NaBH(OAc)3 (529 mg, 2.50 mmol) and then with a solution of 2-(4-methoxynaphthalen-1-yl)acetaldehyde (250 mg, 1.25 mmol) in CH 2 Cl 2 (5 mL) and the mixture was stirred overnight at RT. The reaction was quenched by addition of 15% aq.
  • Step 4 N-ethyl-2-(4-methoxynaphthalen-1-yl)-N-methylethan-1-amine fumarate (I- 78 ⁇ fumarate) N-ethyl-2-(4-methoxynaphthalen-1-yl)-N-methylethan-1-amine (92 mg, 0.38 mmol) was formulated as the fumarate salt according to general procedure B which was collected as white crystals (120 mg, 76%).
  • Example 26 Synthesis of 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-1-ol (I-70)
  • Step 1 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-1-ol (I-70)
  • a solution of N-ethyl-2-(4-methoxynaphthalen-1-yl)-N-methylethan-1-amine (174 mg, 0.72 mmol) in CH 2 Cl 2 (5 mL) at 0 °C was treated with BBr3 (0.34 mL, 3.58 mmol) and the mixture stirred at 0 °C for 1.5 h.
  • the reaction was diluted with CH 2 Cl 2 (15 mL) and cooled to 0 °C before being quenched with sat. aq. Na2CO3 (1 mL).
  • the mixture was diluted with water (15 mL) and adjusted to pH ⁇ 12 with 15% aq. NaOH.
  • the phases were separated and the aqueous was extracted with EtOAc (3 x 15 mL).
  • the combined organics were washed with brine (15 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure.
  • Step 2 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-1-ol fumarate (I-70 ⁇ fumarate) 4-(2-(ethyl(methyl)amino)ethyl)naphthalen-1-ol (90 mg, 0.39 mmol) was formulated as the fumarate salt according to general procedure B which was collected as a pale brown solid (101 mg, 86%).
  • Example 27 Synthesis of N-(2-(4-methoxynaphthalen-1-yl)ethyl)-N-methylpropan- 2-amine (I-79)
  • Step 1 N-(2-(4-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (I-79)
  • a stirred mixture of N-methyl(isopropyl)amine (0.26 mL, 2.50 mmol) in CH 2 Cl 2 (5 mL) at 0 °C was treated with NaBH(OAc)3 (529 mg, 2.50 mmol) and then with a solution of 2-(4-methoxynaphthalen-1-yl)acetaldehyde (250 mg, 1.25 mmol) in CH 2 Cl 2 (5 mL) and the mixture was stirred overnight at room temperature.
  • Step 2 N-(2-(4-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine fumarate (I- 79 ⁇ fumarate) N-(2-(4-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (75 mg, 0.29 mmol) was formulated as the fumarate salt according to general procedure B which was collected as white crystals (92 mg, 73%).
  • Example 28 Synthesis of 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-1-ol (I- 71)
  • Step 1 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-1-ol (I-71)
  • a solution of N-(2-(4-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (206 mg, 0.80 mmol) in CH 2 Cl 2 (5 mL) at 0 °C was treated with BBr3 (0.38 mL, 4.00 mmol) and the mixture stirred at 0 °C for 1.5 h.
  • the reaction was diluted with CH 2 Cl 2 (15 mL) and cooled to 0 °C before being quenched with sat. aq. Na2CO3 (1 mL).
  • the mixture was diluted with water (15 mL) and adjusted to pH ⁇ 12 with 15% aq. NaOH.
  • the phases were separated and the aqueous was extracted with EtOAc (3 x 15 mL).
  • the combined organics were washed with brine (15 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure.
  • Step 2 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-1-ol fumarate (I-71 ⁇ fumarate) 4-(2-(isopropyl(methyl)amino)ethyl)naphthalen-1-ol (115 mg, 0.47 mmol) was formulated as the fumarate salt according to general procedure B which was collected as a brown powder (115 mg, 35%).
  • Example 29 Synthesis of 1-(2-(4-methoxynaphthalen-1-yl)ethyl)pyrrolidine (I-I-81)
  • Step 1 1-(2-(4-methoxynaphthalen-1-yl)ethyl)pyrrolidine (I-81)
  • a stirred mixture of pyrrolidine (0.21 mL, 2.50 mmol) in CH 2 Cl 2 (5 mL) at 0 °C was treated with NaBH(OAc)3 (529 mg, 2.50 mmol) and then with a solution of 2-(4- methoxynaphthalen-1-yl)acetaldehyde (250 mg, 1.25 mmol) in CH 2 Cl 2 (5 mL) and the mixture was stirred overnight at room temperature.
  • the reaction was quenched by addition of 15% aq. NaOH (2 mL), diluted with water (20 mL) and extracted with CH 2 Cl 2 (3 x 15 mL). The combined organics were washed with brine (15 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure.
  • the crude material was purified by flash chromatography (SiO 2 , 0-10% MeOH-NH 3 in CH 2 Cl 2 ) to provide 1-(2- (4-methoxynaphthalen-1-yl)ethyl)pyrrolidine (302 mg, 95%) as a light yellow oil which slowly solidified.
  • Step 2 1-(2-(4-methoxynaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-81 ⁇ fumarate) 1-(2-(4-methoxynaphthalen-1-yl)ethyl)pyrrolidine (101 mg, 0.40 mmol) was formulated as the fumarate salt according to general procedure B which was collected as a white powder (137 mg, 81%).
  • Example 30 Synthesis of 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-1-ol (I-75)
  • Step 1 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-1-ol (I-75)
  • a solution of 1-(2-(4-methoxynaphthalen-1-yl)ethyl)pyrrolidine (200 mg, 0.78 mmol) in CH 2 Cl 2 (5 mL) at 0 °C was treated with BBr3 (0.37 mL, 3.92 mmol) and the mixture stirred at 0 °C for 1.5 h.
  • the reaction was diluted with CH 2 Cl 2 (15 mL) and cooled to 0 °C before being quenched with sat. aq. Na2CO3 (1 mL).
  • the mixture was diluted with water (15 mL) and adjusted to pH ⁇ 12 with 15% aq. NaOH.
  • the phases were separated and the aqueous was extracted with EtOAc (3 x 15 mL).
  • the combined organics were washed with brine (15 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure.
  • the crude material was purified by flash chromatography (SiO 2 , 0-10% MeOH-NH 3 in CH 2 Cl 2 ) to provide 4-(2-(pyrrolidin-1- yl)ethyl)naphthalen-1-ol (40 mg, 21%) as a light red resin.
  • Step 2 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-1-ol fumarate (I-75 ⁇ fumarate) 4-(2-(pyrrolidin-1-yl)ethyl)naphthalen-1-ol (29 mg, 0.12 mmol) was formulated as the fumarate salt according to general procedure B which was collected as a light pink solid (29 mg, 79%).
  • Step 2 2-(4-fluoronaphthalen-1-yl)ethan-1-amine acetate (26) To ice-cold anhydrous THF (100 mL) was added LiAlH4 (1.14 g, 29.9 mmol) in portions, followed by (E)-1-fluoro-4-(2-nitrovinyl)naphthalene (1.3 g, 6.0 mmol) dissolved in minimal anhydrous THF at a rate that maintained a gentle effervescence. The resulting suspension was then refluxed under N2 gas for 16 h. The cooled reaction was then quenched with water (1.2 mL), 3.75 M aq.
  • Step 3 2-(4-fluoronaphthalen-1-yl)-N,N-dimethylethan-1-amine (I-76) To a solution of 2-(4-fluoro-1-naphthyl)ethylamine (200 mg, 1.06 mmol) in (CH 2 Cl) 2 (5 mL) was added sodium triacetoxyborohydride (900 mg, 4.23 mmol) and then aqueous formaldehyde (37% w/w, 0.2 mL, 7.26 mmol) at RT. The reaction was stirred at RT for 1 h, and then quenched with saturated aq. NaHCO 3 (25 mL) and diluted with 50 mL of CH 2 Cl 2 .
  • sodium triacetoxyborohydride 900 mg, 4.23 mmol
  • formaldehyde 37% w/w, 0.2 mL, 7.26 mmol
  • Step 4 2-(4-fluoronaphthalen-1-yl)-N,N-dimethylethan-1-amine fumarate (I- 76 ⁇ fumarate) 2-(4-fluoronaphthalen-1-yl)-N,N-dimethylethan-1-amine (120 mg, 0.55 mmol) was formulated as the fumarate salt according to general procedure B and was isolated as white crystals (97 mg, 53%).
  • Example 32 Synthesis of N-ethyl-2-(6-methoxynaphthalen-1-yl)-N-methylethan-1- amine (I-38)
  • Step 1 Methyl 6-methoxy-1-naphthoate (28)
  • dimethyl sulfate 20.1 g, 159.4 mmol
  • K2CO3 27.5 g, 199.3 mmol
  • Step 2 (6-methoxynaphthalen-1-yl)methanol (29) To an ice-cold solution of methyl 6-methoxy-1-naphthoate (8.0 g, 37.0 mmol) in THF (80 mL) was added dropwise a suspension of LiAlH4 (2.1 g, 55.5 mmol) in THF (80 mL) under an atmosphere of nitrogen gas. The resulting reaction mixture was stirred at RT for 1 h and then the reaction was cooled again and treated dropwise with 2M HCl (80 mL). TLC indicated completion of the reaction, so the reaction mixture was concentrated under reduced pressure and residue was dissolved in water (80 mL) and extracted with EtOAc (80 mL x 3).
  • Step 3 6-methoxy-1-naphthaldehyde (30) To a stirred solution of (6-methoxynaphthalen-1-yl)methanol (5.9 g, 31.3 mmol) in DCM (80 mL) was added a suspension of pyridinium chlorochromate (13.5 g, 62.7 mmol) in DCM (97 mL) at RT under an atmosphere of nitrogen gas. The resulting reaction mixture was stirred at RT for 1 h and TLC indicated the reaction was complete, so the reaction mixture was diluted with diethyl ether (118 mL). The suspension was filtered through a celite plug and further washed with diethyl ether (50 mL x 3).
  • Step 4 6-methoxy-1-(2-methoxyvinyl)naphthalene (31)
  • 6-methoxy-1-naphthaldehyde 5.2 g, 27.9 mmol
  • anhydrous THF 52 mL
  • (methoxymethyl)triphenyl phosphonium chloride 23.9 g, 69.8 mmol
  • Step 5 2-(6-methoxynaphthalen-1-yl)acetaldehyde (32) To a stirred solution of 6-methoxy-1-(2-methoxyvinyl)naphthalene (1.0 g, 4.66 mmol) in THF (10 mL) was added 5 M aq. HCl (5 mL) at RT and the resulting reaction mixture was stirred at 50 oC for 1 h. The reaction mixture was then quenched with saturated aq. NaHCO 3 (20 mL) and extracted with 10% MeOH in DCM (40 mL x 3). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford the title compound as a yellow liquid (0.85 g, 91%).
  • Step 6 N-ethyl-2-(6-methoxynaphthalen-1-yl)-N-methylethan-1-amine formate (I- 31 ⁇ formate)
  • 2-(6-methoxynaphthalen-1-yl)acetaldehyde 0.8 g, 3.99 mmol
  • N-methylethanamine (0.47 g, 8.00 mmol)
  • the reaction was cooled in an ice-bath and NaBH(OAc)3 (2.1 g, 9.98 mmol) was added portion wise.
  • the resulting reaction mixture was stirred at RT for 16 h.
  • reaction mixture was poured into water (40 mL) and extracted with 10% MeOH in DCM (40 mL x 3). The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (product eluted at 1% MeCN in water containing 0.05% formic acid) to afford the title compound as the formate salt which was a yellow resin (100 mg, 9%).
  • Step 7 N-ethyl-2-(6-methoxynaphthalen-1-yl)-N-methylethan-1-amine fumarate (I- 31 ⁇ fumarate) N-ethyl-2-(6-methoxynaphthalen-1-yl)-N-methylethan-1-amine formate (100 mg, 0.35 mmol) was reformulated as the fumarate salt according to general procedure B which was isolated as a light-brown solid (70 mg, 56%).
  • Example 33 Synthesis of 5-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol (I-38) Step 1: 5-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol (I-38) To a stirred solution of N-ethyl-2-(2-methoxynaphthalen-1-yl)-N-methylethan-1- amine (700 mg, 2.87 mmol) in CH 2 Cl 2 (7 mL) was added 1 M BBr3 in CH 2 Cl 2 (3.5 mL) at 0 oC under an atmosphere of nitrogen gas. The resulting reaction mixture was stirred at RT for 16 h before being poured into saturated aq.
  • Step 2 5-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol fumarate (I-38 ⁇ fumarate) 5-(2-(ethyl(methyl)amino)ethyl)naphthalen-2-ol (350 mg, 1.53 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (120 mg, 23%).
  • Example 34 Synthesis of N-(2-(6-methoxynaphthalen-1-yl)ethyl)-N-methylpropan- 2-amine (I-32)
  • Step 1 N-(2-(6-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (I-32)
  • 2-(6-methoxynaphthalen-1-yl) acetaldehyde 450 mg, 2.24 mmol
  • DCE 9 mL
  • N-methylisopropylamine 490 mg, 6.74 mmol
  • Step 2 N-(2-(6-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine fumarate (I- 32 ⁇ fumarate) N-(2-(6-methoxynaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (150 mg, 0.58 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a pale-yellow solid (53 mg, 25%).
  • Step 2 5-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol fumarate (I-39 ⁇ fumarate) 5-(2-(isopropyl(methyl)amino)ethyl)naphthalen-2-ol (110 mg, 0.45 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a white solid (70 mg, 43%).
  • Example 36 Synthesis of 1-(2-(6-methoxynaphthalen-1-yl)ethyl)azetidine (I-34)
  • Step 1 1-(2-(6-methoxynaphthalen-1-yl)ethyl)azetidine (I-34)
  • azetidine (0.76 g, 13.48 mmol) at RT under an atmosphere of nitrogen gas.
  • the reaction was cooled in an ice-bath and NaBH(OAc)3 (2.38 g, 11.23 mmol) was added portion wise.
  • Step 2 1-(2-(6-methoxynaphthalen-1-yl)ethyl)azetidine fumarate (I-34 ⁇ fumarate) 1-(2-(6-methoxynaphthalen-1-yl)ethyl)azetidine (80 mg, 0.33 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a yellow solid (90 mg, 76%).
  • Example 37 Synthesis of 5-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol (I-41)
  • Step 1 5-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol (I-41)
  • To a stirred solution of 1-(2-(6-methoxynaphthalen-1-yl)ethyl)azetidine (450 mg, 1.86 mmol) in CH 2 Cl 2 (4.5 mL) was added 1 M BBr3 in CH 2 Cl 2 (2.3 mL) at 0 oC under an atmosphere of nitrogen gas.
  • the resulting reaction mixture was stirred at RT for 2 h before being poured into saturated aq.
  • Step 2 5-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol fumarate (I-41 ⁇ fumarate) 5-(2-(azetidin-1-yl)ethyl)naphthalen-2-ol (200 mg, 0.88 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (150 mg, 50%).
  • Example 38 Synthesis of 1-(2-(6-methoxynaphthalen-1-yl)ethyl)pyrrolidine (I-35)
  • Step 1 1-(2-(6-methoxynaphthalen-1-yl)ethyl)pyrrolidine (I-35)
  • pyrrolidine (1.59 g, 22.5 mmol) at RT under an atmosphere of nitrogen gas.
  • the reaction was cooled in an ice-bath and NaBH(OAc)3 (3.9 g, 18.8 mmol) was added portion wise.
  • Step 2 1-(2-(6-methoxynaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-35 ⁇ fumarate) 1-(2-(6-methoxynaphthalen-1-yl)ethyl)pyrrolidine (80 mg, 0.31 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a yellow solid (90 mg, 77%).
  • Example 39 Synthesis of 5-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol (I-42) Step 1: 5-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol (I-42) To a stirred solution of 1-(2-(6-methoxynaphthalen-1-yl)ethyl)pyrrolidine (350 mg, 1.37 mmol) in CH 2 Cl 2 (5 mL) was added 1 M BBr3 in DCM (1.8 mL) at 0 oC under an atmosphere of nitrogen gas. The resulting reaction mixture was stirred at RT for 2 h before being poured into saturated aq.
  • Step 2 5-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol fumarate (I-42 ⁇ fumarate) 5-(2-(pyrrolidin-1-yl)ethyl)naphthalen-2-ol (70 mg, 0.29 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as a pale-yellow solid (80 mg, 77%).
  • Example 40 Synthesis of 2-(6-fluoronaphthalen-1-yl)-N,N-dimethylethan-1-amine (I-44) Step 1: Ethyl 2-(6-fluoro-3,4-dihydronaphthalen-1-yl)acetate (34) NaOEt (2.07 g, 30.5 mmol) was added to anhydrous EtOH (30 mL), followed by triethyl phosphonoacetate (7.25 mL, 36.5 mmol) and the resulting solution was stirred for 10 min.
  • 6-fluoro-1H-tetralone (5 g, 30.5 mmol) was added to the reaction and stirred at reflux under N2 gas for 2.5 h at which point a further portion of NaOEt (1.04 g, 15.3 mmol) and triethyl phosphonoacetate (3.63 mL, 36.5 mmol) in 15 mL of anhydrous EtOH, that had been stirred for 10 min, was added at RT. The reaction was further refluxed under N2 gas for 16 h.
  • Step 2 Ethyl 2-(6-fluoronaphthalen-1-yl)acetate (35) To a solution of containing a mixture of ethyl (6-fluoro-3,4-dihydro-1- naphthyl)acetate and ethyl (6-fluoro-1,2,3,4-tetrahydro-1-naphthylidene)acetate (3.4 g, 14.5 mmol) in d-limonene (93% purity, 47 mL) was added 10% Pd/C (3.1 g). The resulting suspension was brought to reflux at 180 oC and within 1 h, an exotherm accompanied by vigorous gas evolution occurred.
  • Step 3 2-(6-fluoronaphthalen-1-yl)acetic acid (36) To a stirred mixture of ethyl (6-fluoro-1-naphthyl)acetate (720 mg, 3.10 mmol) in a THF:H2O (1:1, 10 mL) solution was added LiOH (371 mg, 15.5 mmol) in one portion. Stirring was continued for 16 h before being concentrated under a stream of N2 gas. The residue was diluted with H2O (15 mL) and washed with Et2O (2 x 25 mL). The aqueous phase was then adjusted to pH 1-2 by dropwise addition of 6 M aq. HCl and then extracted with CH 2 Cl 2 (20 mL x 3).
  • Step 4 2-(6-fluoronaphthalen-1-yl)-N,N-dimethylacetamide (37) To a suspension of (6-fluoro-1-naphthyl)acetic acid (500 mg, 2.45 mmol) and EDC.HCl (939 mg, 4.90 mmol) in DMF (5 mL) was added HOBt hydrate (80% w/w, 937 mg, 4.90 mmol), Me2NH.HCl (998 mg, 12.20 mmol), and DIPEA (4.27 mL, 24.50 mmol) at RT.
  • Step 5 2-(6-fluoronaphthalen-1-yl)-N,N-dimethylethan-1-amine hydrochloride (I-44 ⁇ HCl)
  • N,N-dimethyl(6-fluoro-1-naphthyl)acetamide 350 mg, 1.51 mmol
  • borane dimethylsulfide complex 2 M in THF, 1.5 mL, 4.32 mmol
  • An equal amount of borane dimethylsulfide complex (1.5 mL) was added and stirring was continued at 60 oC for a further 1 h.
  • the hot solution was then quenched by sequential addition of 6 M aq. HCl (2 mL) then MeOH (3 mL) and stirring continued for a further 15 min.
  • the reaction pH was then adjusted to 11-12 with 5 M aq. NaOH.
  • the suspension was then extracted with EtOAc (100 mL), the organic layer was then washed with saturated aq. Na2CO3 (10 mL x 3) and then 20 mL of a 1:1 solution of brine and saturated aq. Na2CO3.
  • the organic layer was dried over anhydrous Na2SO4, filtered, and the filtrate concentrated in vacuo.
  • the residue was purified by flash chromatography (0 to 20% EtOAc in hexane) to afford the title compound as the borane complex.
  • Example 41 Synthesis of N-ethyl-2-(6-fluoronaphthalen-1-yl)-N-methylethan-1- amine (I-45)
  • Step 1 N-ethyl-2-(6-fluoronaphthalen-1-yl)-N-methylacetamide (38)
  • EDC.HCl 563 mg, 2.94 mmol
  • DMF 5 mL
  • HOBt Hydrate 80% w/w, 562 mg, 2.94 mmol
  • N-methylethylamine (0.63 mL, 7.35 mmol
  • Step 2 N-ethyl-2-(6-fluoronaphthalen-1-yl)-N-methylethan-1-amine (I-45) To a solution of N-ethyl-2-(6-fluoronaphthalen-1-yl)-N-methylacetamide (170 mg, 0.69 mmol) in anhydrous THF (5 mL) was added borane dimethylsulfide complex (2 M in THF, 1.4 mL, 2.77 mmol) under N2 gas and the reaction was stirred at reflux for 1 h. Upon completion, the hot solution was quenched by sequential addition 6 M aq. HCl (3 mL) followed by MeOH (5 mL).
  • Step 3 N-ethyl-2-(6-fluoronaphthalen-1-yl)-N-methylethan-1-amine fumarate (I- 45 ⁇ fumarate) N-ethyl-2-(6-fluoronaphthalen-1-yl)-N-methylethan-1-amine (80 mg, 0.35 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as white crystals (75 mg, 60%).
  • Example 42 Synthesis of N-(2-(6-fluoronaphthalen-1-yl)ethyl)-N-methylpropan-2- amine (I-46) Step 1: 2-(6-fluoronaphthalen-1-yl)-N-isopropyl-N-methylacetamide (39) To a suspension of (6-fluoro-1-naphthyl)acetic acid (300 mg, 1.47 mmol) and EDC.HCl (563 mg, 2.94 mmol) in DMF (5 mL) was added HOBt Hydrate (80% w/w, 562 mg, 2.94 mmol) and N-methyl(isopropyl)amine (0.77 mL, 7.35 mmol) at RT.
  • Step 2 N-(2-(6-fluoronaphthalen-1-yl)ethyl)-N-methylpropan-2-amine (I-46) To a solution of 2-(6-fluoronaphthalen-1-yl)-N-isopropyl-N-methylacetamide (370 mg, 1.43 mmol) in anhydrous THF (10 mL) was added borane dimethylsulfide complex (2 M in THF, 2.85 mL, 5.71 mmol) under N2 gas and the reaction was stirred at reflux for 1 h. Upon completion, the hot solution was quenched by sequential addition of 6 M aq. HCl (2 mL), followed by MeOH (5 mL).
  • the solution was then stirred at reflux for 1 h, and then concentrated under a stream of N2 gas.
  • the aqueous residue was neutralised with saturated aq. Na2CO3 and then made a basic with 1 mL of 15% aq. NaOH.
  • the suspension was extracted with CH 2 Cl 2 (50 mL x 3), and the combined organics washed with saturated aq. Na2CO3 (20 mL x 3) and brine (50 mL).
  • the organic layer was dried over anhydrous Na2SO4, filtered, and the filtrate concentrated in vacuo.
  • Step 3 N-(2-(6-fluoronaphthalen-1-yl)ethyl)-N-methylpropan-2-amine fumarate (I- 46 ⁇ fumarate) Fumaric acid (142 mg, 1.22 mmol) was dissolved in minimal refluxing acetone and then treated with a solution of N-(2-(6-fluoronaphthalen-1-yl)ethyl)-N-methylpropan- 2-amine (300 mg, 1.22 mmol) dissolved in minimal acetone before being concentrated under a stream of N 2 gas to produce an oil.
  • Step 2 2-(6-fluoronaphthalen-1-yl)ethyl methanesulfonate (41)
  • 2-(6-fluoronaphthalen-1-yl)ethan-1-ol 1.2 g, 6.31 mmol
  • DCM 14 mL
  • TEA 2.5 mL, 18.9 mmol
  • MsCl 1.5 mL, 9.47 mmol
  • reaction mixture was stirred at RT for 2 h.
  • the reaction mixture was quenched with water (100 mL) and extracted with EtOAc (100 mL x 2).
  • Step 3 1-(2-(6-fluoronaphthalen-1-yl)ethyl)azetidine (I-49) To a stirred solution of 2-(6-fluoronaphthalen-1-yl)ethyl methanesulfonate (500 mg, 1.86 mmol) in MeCN (5 mL) was added K2CO3 (1.2 g, 9.32 mmol) and azetidine (130 mg, 2.23 mmol) at RT and the reaction mixture was then stirred at 80 oC for 16 h. The reaction mixture was then poured into water (70 mL) and extracted with EtOAc (70 mL x 2).
  • Step 4 1-(2-(6-fluoronaphthalen-1-yl)ethyl)azetidine fumarate (I-49 ⁇ fumarate) 1-(2-(6-fluoronaphthalen-1-yl)ethyl)azetidine (180 mg, 0.78 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (225 mg, 83%).
  • Example 44 Synthesis of 1-(2-(6-fluoronaphthalen-1-yl)ethyl)pyrrolidine (I-50)
  • Step 1 1-(2-(6-fluoronaphthalen-1-yl)ethyl)pyrrolidine (I-50)
  • K2CO3 1.2 g, 9.32 mmol
  • pyrrolidine 150 mg, 2.24 mmol
  • Step 2 1-(2-(6-fluoronaphthalen-1-yl)ethyl)pyrrolidine fumarate (I-50 ⁇ fumarate) 1-(2-(6-fluoronaphthalen-1-yl)ethyl)pyrrolidine (220 mg, 0.90 mmol) was formulated as the fumarate salt according to general procedure B which was isolated as an off-white solid (250 mg, 78%).
  • stably transfected cells expressing the receptor of interest (HEK293 for 5-HT2A and 5-HT2C; CHO-K1 for 5- HT2B) were grown and plated in a 384 well plate and incubated at 37 °C and 5% CO2 overnight.
  • Reference compounds were 4-fold serially diluted and the screening compounds were 3-fold serially diluted in 100% DMSO for 10 points using Agilent Bravo, and 750 nL was added to a 384 well compound plate using Echo along with 30 ⁇ L assay buffer.
  • the fluorescent dye was then added to the assay plate along with assay buffer to a final volume of 40 ⁇ L.
  • the cell plate was incubated for 50 min at 37 °C and 5% CO 2 and placed into the FLIPR Tetra along with the compound plate.10 ⁇ L of references and compounds were then transferred from the compound plate into the cell plate and the fluorescent signal was read.
  • In vivo pharmacokinetics experiments Prospective studies for in vivo pharmacokinetics will be conducted using established procedures in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, and the study protocols will be reviewed and approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee.
  • mice will have access to food and water ad libitum throughout the pre- and post-dose sampling period.
  • the formulation of each compound will be prepared by dissolving solid compound in an appropriate solvent using vortexing.
  • a maximum of three blood samples will be obtained from each mouse, with plasma samples being taken via submandibular bleed (approximately 120 ⁇ L).
  • blood samples will be processed by standard methods and analysed by LCMS.
  • whole brain samples will be taken by rapid removal from the carcass soon after the blood collection. The whole brains will be blotted to remove excess blood, placed into pre-weighed polypropylene vials, and weighed. The brains will be snap frozen in dry ice and subsequently stored frozen (-80 °C) until analysis.
  • Bioanalytical Method Summary Concentrations of test compound in plasma and tissue samples will be determined using an LCMS/MS method validated for linearity, accuracy, precision, matrix factor and recovery.
  • Test compound standard solutions will be diluted from a concentrated stock solution (32 mM in H2O) using 50% ACN in H2O (v/v) and a calibration curve was prepared in a matched matrix to the test samples.
  • Plasma The plasma calibration curve will be prepared by spiking aliquots of blank mouse plasma (25 ⁇ L) with test compound standard solutions (5 ⁇ L) and internal standard solution (5 ⁇ L of diazepam, 5 ⁇ g/mL in 50% acetonitrile in water). Test plasma samples (25 ⁇ L) will be thawed, mixed, and then spiked with internal standard solution (5 ⁇ L). Plasma protein precipitation can be performed by addition of acetonitrile (3-fold volume ratio) and thorough vortex mixing.
  • tissue samples Pre-weighed tissue samples (brain) will be prepared according to general methods, for example: homogenised using a glass rod in buffer containing an EDTA/potassium fluoride solution (0.1 M / 4 mg/mL) as a stabilisation cocktail to minimise the potential for ex vivo degradation (3 mL cocktail/g tissue).
  • mice will be purchased from the Jackson Laboratory (Bar Harbor, ME, USA) at 5 ⁇ 6 weeks of age and allowed at least 1 ⁇ 2 weeks to acclimate to the animal research facility. Mice will be initially group housed 3 ⁇ 5 per cage during acclimation and housed in a 12 h light ⁇ dark cycle throughout the study, with lights on at 0700 h. Food and water will be available ad libitum except during testing. Cohorts of 20 ⁇ 24 mice will be used for each test drug. The mice will be subjected to experimental testing once every 1 ⁇ 2 weeks for 2 ⁇ 3 months to complete dose ⁇ effect curves and antagonist experiments. A minimum of 7 days between treatments will be utilized to avoid any tolerance to effects of repeated drug administration.
  • mice will be tested first in dose ⁇ response studies to assess the effects of each compound at doses from 0.03 to 30 mg/kg s.c. and will be subsequently tested in antagonist reversal studies utilizing pretreatment with M100907 and WAY100635. All experiments will be conducted from 0900 to 1700 local time during the light phase, as sensitivity of rodents to other tryptamine psychedelics is diurnal, with maximal HTR observed in the middle of the light phase.
  • mice will be acclimated to the testing room in their home cage for at least 1 h prior to experimental sessions. Behavioral test sessions will be carried out in Tru Scan mouse locomotor arenas equipped with photobeam arrays (Coulbourn Instruments, Holliston, MA, USA), which will be modified with cylindrical inserts and transparent floors useful in detecting mouse HTR. Subcutaneous Temperature Transponder Implants. At least 1 week prior to the start of the experiments, mice will recieve s.c.
  • mice implanted temperature transponders (14 ⁇ 2 mm, model IPTT-300, Bio Medic Data Systems, Inc., Seaford, DE, USA) under brief isoflurane anesthesia. Mice were single housed post implant for the remainder of the study to protect the transponder from removal by cage mates. Temperature will be determined noninvasively using a handheld receiver that is sensitive to signals emitted from the implanted transponders. Prior to each experiment, mouse body weight and temperature will be recorded. Mice will then be placed into testing chambers for acclimation. In dose ⁇ response studies, after a brief 5 min acclimation, mouse body temperature will be recorded for baseline measurement, mice will receive s.c.
  • locomotor activity will be monitored via photobeam tracking of movements in the horizontal plane to yield distance traveled in centimeter. HTR will be monitored by the analysis of GoPro Hero Black 7 video recordings (120 frames per sec and 960p resolution) using a commercially available software package from Clever Sys Inc. (Reston, VA, USA).82 post-treatment body temperature values will also be recorded, and temperature data is represented as change from pretreatment baseline. In antagonist reversal experiments, mice will recieve a s.c. injection of either receptor antagonists or vehicle and were returned to the testing chamber for 30 min. During this period, locomotor activity will be monitored to examine the potential effects of antagonist treatment on general behavior or movement.
  • mice At 30 min after antagonist administration, mice will be given test drug or vehicle and returned to the chambers for an additional 30 min of video recording used for analyses. All statistical analyses will be conducted using GraphPad Prism 9 (La Jolla, CA, USA). Dose ⁇ response data from mouse experiments will be analyzed using nonlinear regression, and potency values will be determined from the rising phase of the curves for HTR measures. For mouse studies, one-way ANOVA with Dunnett’s post hoc test will be used to compare all conditions to vehicle controls (0 or 0,0) in dose ⁇ response and antagonist experiments. Mean HTR count, distance traveled, and temperature change for each condition will be used for statistical comparisons. Alpha will be set at 0.05 for all analyses.
  • ASR Acute Restraint Stressor
  • TST Tail Suspension Test
  • Mice will be housed in groups of 10 in a large cage (47 x 25 x 15 cm) on a 12-hour light cycle (lights on: 0700) and provided ad libitum food and water except during acute restraint stress and tail-suspension testing. Temperature will be maintained at 20-24 °C, and all rooms (colony and testing rooms) had similar lighting intensity. All aspects of this work including housing, experimentation, and animal disposal were performed in accordance with the “Guide for the Care and Use of Laboratory Animals: Eighth Edition” (The National Academys Press, Washington, DC, 2011) in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. All experiments will be conducted between 0900 to 1700 local time, during the light phase.
  • Acute Restraint Stress (ARS) Procedure Mice will be moved from the colony room to the procedure room in which ARS will be performed.
  • ARS Acute Restraint Stress
  • mice will recieve oral gavage of water (10 ml/kg) to avoid dehydration, and then will be individually restrained for 5 hours in a clear plastic cylinder (50 mL centrifuge tube with air holes drilled for ventilation), positioned horizontally on a bench with bench towel to absorb urine. This restraint will prevent physical movement, without causing pain. Restrainers will be washed with veterinary disinfectant between mice. Drug Administration: Immediately after the 5-hour ARS procedure, mice will be removed from the restrainers, placed in their home cage, and transported to the room in which Tail Suspension Test will be be conducted.
  • mice will then receive intraperitoneal injection with vehicle, ketamine (10 mg/kg), test compounds (over a range of doses), and will be placed back in their home cage.10 minutes after treatment, animals will undergo the Tail Suspension Test.
  • Tail Suspension Test (TST) Procedure Mice will be individually suspended on the edge of a shelf, 58 cm above a tabletop, using adhesive tape placed approximately 1 cm from the tip of the tail, for a total duration of 7 minutes. Using a stopwatch, the experimenters blinded to treatment groups will record the duration of immobility (defined as hanging passively and motionless) during the 5 minutes spanning from 2-7 minutes. The data from 0-2 minutes will not be recorded. Mice undergoing TST will never be in view of other mice.
  • mice will be euthanized via carbon dioxide inhalation.
  • Statistical Analysis will be conducted using GraphPad Prism 9 (La Jolla, CA, USA), using a priori simple effect comparisons within a one-way ANOVA to compare the test compounds to the Vehicle condition, on time spent immobile (in seconds). STATEMENTS 1.
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each selected from hydrogen, halogen, OR 13 , C 1 -2 alkyl, C 1 -2 haloalkyl, C 1 -2 alkoxy and C 1 -2 haloalkoxy; preferably hydrogen, halogen, OR 13 , C 1 -2 alkyl; or hydrogen, fluoro, and OR 13 .
  • R 1 and R 2 are each independently selected from hydrogen, C 1 - 4 alkyl, C 1 -4 haloalkyl, C 3 -4 cycloalkyl, C4-5 alkylenecycloalkyl, and C 7 alkylenearyl. 53.
  • R 8 is selected from -OH, -OC 1-6 alkoxy and halo.
  • R 4 and R 6 are each H.
  • the compound of statement 1 or 96 or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph and/or prodrug thereof, wherein the compound is any one of Compounds I-78 to I-81, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.
  • a pharmaceutical composition comprising a compound of any one of the preceding statements or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof; and a pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprising a compound of any one of statements 1 to 97 or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof; an additional therapeutic agent; and a pharmaceutically acceptable excipient.
  • a medicament comprising a compound of any one of statements 1 to 97 or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof.
  • a method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering to a subject in need thereof a compound of any one of statements 1 to 97, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, or a pharmaceutical composition of statement 98 or 99, or the medicament of statement 100. 102.
  • a method of treating a disease, disorder or condition by activation of a serotonin receptor comprising administering to a subject in need thereof a compound of any one of statements 1 to 97, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, or a pharmaceutical composition of statement 98 or 99, or the medicament of statement 100; in combination with another known agent useful for treatment of a disease, disorder or condition by activation of a serotonin receptor. 103.
  • a method of treating a mental illness comprising administering to a subject in need thereof a compound of any one of statements 1 to 97, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, or a pharmaceutical composition of statement 98 or 99, or the medicament of statement 100. 104.
  • the method of statement 103 wherein the mental illness is selected from anxiety disorders; depression; mood disorders; psychotic disorders; impulse control and addiction disorders; drug addiction; obsessive-compulsive disorder (OCD); post- traumatic stress disorder (PTSD); stress response syndromes; dissociative disorders; depersonalization disorder; factitious disorders; sexual and gender disorders; somatic symptom disorders; hallucinations; delusions; psychosis; and combinations thereof.
  • the mental illness is selected from anxiety disorders; depression; mood disorders; psychotic disorders; impulse control and addiction disorders; drug addiction; obsessive-compulsive disorder (OCD); post- traumatic stress disorder (PTSD); stress response syndromes; dissociative disorders; depersonalization disorder; factitious disorders; sexual and gender disorders; somatic symptom disorders; hallucinations; delusions; psychosis; and combinations thereof.
  • a method for treating a central nervous system (CNS) disease, disorder or condition and/or a neurological disease, disorder or condition comprising administering to a subject in need thereof a compound of any one of statements 1 to 97, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, or a pharmaceutical composition of statement 98 or 99, or the medicament of statement 100.
  • CNS central nervous system
  • the CNS disease, disorder or condition and/or neurological disease, disorder or condition is selected from neurological diseases including neurodevelopmental diseases and neurodegenerative diseases such as Alzheimer’s disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson’s disease and Parkinsonian related disorders such as Parkinson dementia, corticobasal degeneration, and supranuclear palsy; epilepsy; CNS trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington’s disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder and attention deficit disorders; restless leg syndrome; Tourette's syndrome; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system including eating disorders such as anorexia
  • a method for increasing neuronal plasticity and/or increasing dendritic spine density comprising contacting a neuronal cell with a compound of any one of statements 1 to 97, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, or a pharmaceutical composition of statement 98 or 99, or the medicament of statement 100, in an amount sufficient to increase neuronal plasticity and/or increase dendritic spine density of the neuronal cell.
  • a method of treating weight comprising administering an effective amount of a compound of any one of statements 1 to 97, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, or a pharmaceutical composition of statement 98 or 99, or the medicament of statement 100 to a subject in need thereof. 109.
  • weight gain is selected from the group consisting of treating weight gain; weight loss; metabolic disorder; weight gain associated with pharmaceutical intervention; weight gain associated with a mental illness (including those described herein); eating disorders such as anorexia, bulimia, cachexia, etc.; eating behaviour; obesity; diabetes; insulin resistance; pre-diabetes; glucose intolerance; hyperlipidemia; and cardiovascular disease.
  • eating disorders such as anorexia, bulimia, cachexia, etc.
  • eating behaviour obesity; diabetes; insulin resistance; pre-diabetes; glucose intolerance; hyperlipidemia; and cardiovascular disease.
  • a method for activating a serotonin receptor in a cell comprising administering a compound of any one of statements 1 to 97, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer, metabolite, polymorph or prodrug thereof, or a pharmaceutical composition of statement 98 or 99, or the medicament of statement 100, to the cell.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), leurs procédés de synthèse, et leur utilisation dans le traitement de maladies mentales ou de troubles du système nerveux central.
PCT/AU2024/051322 2023-12-06 2024-12-06 Composés actifs au niveau du récepteur sérotonergique 5-ht2a Pending WO2025118034A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2023903954 2023-12-06
AU2023903954A AU2023903954A0 (en) 2023-12-06 Compounds

Publications (1)

Publication Number Publication Date
WO2025118034A1 true WO2025118034A1 (fr) 2025-06-12

Family

ID=95981195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2024/051322 Pending WO2025118034A1 (fr) 2023-12-06 2024-12-06 Composés actifs au niveau du récepteur sérotonergique 5-ht2a

Country Status (1)

Country Link
WO (1) WO2025118034A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082847A1 (fr) * 2013-12-05 2015-06-11 Les Laboratoires Servier Nouveau procede de synthese de l'agomelatine
CN104725249A (zh) * 2013-12-20 2015-06-24 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
WO2018210992A1 (fr) * 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine
WO2019140265A1 (fr) * 2018-01-12 2019-07-18 President And Fellows Of Harvard College Inhibiteurs d'arnt synthétase
WO2023130181A1 (fr) * 2022-01-04 2023-07-13 Bright Minds Biosciences Inc. Phénéthylamines et leurs procédés de préparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082847A1 (fr) * 2013-12-05 2015-06-11 Les Laboratoires Servier Nouveau procede de synthese de l'agomelatine
CN104725249A (zh) * 2013-12-20 2015-06-24 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
WO2018210992A1 (fr) * 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Dérivés de pyrimidine
WO2019140265A1 (fr) * 2018-01-12 2019-07-18 President And Fellows Of Harvard College Inhibiteurs d'arnt synthétase
WO2023130181A1 (fr) * 2022-01-04 2023-07-13 Bright Minds Biosciences Inc. Phénéthylamines et leurs procédés de préparation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY 12 December 2013 (2013-12-12), XP093332917, Database accession no. 1493657-23-0 *
DATABASE REGISTRY 16 April 2012 (2012-04-16), XP093332919, Database accession no. 1369268-21-2 *
DATABASE REGISTRY 8 August 2017 (2017-08-08), XP093332915, Database accession no. 2109955-01-1 *
HIEBLE J. P., ET AL.: "COMPARISON OF CENTRAL AND PERIPHERAL ALPHA 1-ADRENOCEPTORS.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, DE, vol. 318., no. 04., 1 January 1982 (1982-01-01), DE , pages 267 - 273., XP000853994, ISSN: 0028-1298, DOI: 10.1007/BF00501164 *

Similar Documents

Publication Publication Date Title
US20250101038A1 (en) Compounds
US20250163044A1 (en) Compounds
WO2021216770A1 (fr) Composés de tétrahydroquinazoline substitués utilisés comme inhibiteurs de kras
EP3697781B1 (fr) Antagonistes du récepteur muscarinique de l'acétylcholine m4
JP2018076365A (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
JPWO2020128925A5 (fr)
US20250361233A1 (en) Compounds For Activating Serotonin Receptor
WO2022198003A1 (fr) Modulateurs allostériques négatifs du récepteur 2 du glutamate métabotropique
WO2025118034A1 (fr) Composés actifs au niveau du récepteur sérotonergique 5-ht2a
WO2025104490A1 (fr) Dérivés d'indole utilisés en tant qu'agents sérotoninergiques utiles pour le traitement de troubles associés
US20250333371A1 (en) Compounds
US12428380B2 (en) Compounds
CN109734712A (zh) 芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
WO2025104491A1 (fr) Dérivés indoles utilisés en tant qu'agents sérotoninergiques utiles pour le traitement de troubles associés
WO2025166273A1 (fr) Nouveaux analogues de la classe oxa-iboga d'agents thérapeutiques
WO2022212815A1 (fr) Dérivés de quinazoline-4(3h)-one utilisés en tant que modulateurs allostériques négatifs du récepteur métabotropique du glutamate 2
CN109776373A (zh) 酰胺取代的吡咯烷酰胺衍生物及其用途
CN109776374A (zh) 酰基取代的吡咯烷酰胺衍生物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24898999

Country of ref document: EP

Kind code of ref document: A1